Curriculum Vitae

JONATHAN D. LICHT, MD

**ADDRESS**

 University of Florida Health Cancer Center

 Cancer/Genetics Research Complex

 2033 Mowry Road, Ste. 145

 Gainesville, FL 32610

 352-273-8413 (Work)

 847-612-7174 (Cell)

 jdlicht@ufl.edu (Work)

 jdlicht@mac.com (personal)

**PLACE OF BIRTH** New York, New York

ACADEMIC APPOINTMENTS

 1988-1991 Instructor in Medicine, Harvard Medical School

 1991-1996 Assistant Professor, Brookdale Center for Developmental and Molecular Biology and Department of Medicine

 1996-1998 Associate Professor, Brookdale Center for Developmental and Molecular Biology and Department of Medicine

 1998-2001 Associate Professor-With Tenure,

 Derald H. Ruttenberg Cancer Center

 and Department of Medicine,

 Mount Sinai School of Medicine

 2001-2003 Irene and Dr. Arthur M. Fishberg Professor of Medicine

 Derald H. Ruttenberg Cancer Center

 and Department of Medicine,

 Mount Sinai School of Medicine

 2002-2003 Vice Chairman for Research

 Department of Medicine

 Mount Sinai School of Medicine

 2003-2005 Chief, Division of Hematology/Oncology

 Department of Medicine

 Ezra M. Greenspan Professor in Clinical Cancer Therapeutics

 Mount Sinai School of Medicine

 2004-2005 Associate Dean for Cancer Programs

 Mount Sinai School of Medicine

 2006-2015 Chief, Division of Hematology/Oncology

 Department of Medicine

 Northwestern University Feinberg School of Medicine

 2006-2015 Associate Director for Clinical Sciences

 Robert H. Lurie Comprehensive Cancer Center of

 Northwestern University

2007-2015 Johanna Dobe Professor of Hematology/Oncology

 Northwestern University Feinberg School of Medicine

2014-2015 Professor, Department of Biochemistry and Molecular Genetics

 Northwestern University Feinberg School of Medicine

10/1/15-2019 Adjunct Professor of Medicine

 Adjunct Professor of Biochemistry and Molecular Genetics

 Northwestern University Feinberg School of Medicine

10/1/15- Professor, Department of Medicine

 University of Florida College of Medicine

10/1/15- Professor, Department of Biochemistry and Molecular Biology

 University of Florida College of Medicine

10/1/15- Director, The University of Florida Health Cancer Center

 Marshall E. Rinker Sr. Foundation

 and David B. and Leighan R. Rinker Professor

**HOSPITAL APPOINTMENTS**

 1998-1991 Clinical Associate, Dana-Farber Cancer Institute

 & Brigham & Women's Hospital, Boston, MA

* 1. Assistant Attending Physician, Mount Sinai Medical Center

2003-2006 Attending Physician, Mount Sinai Medical Center

2006-2015 Attending Physician, Northwestern Memorial Hospital

2015- Attending Physician University of Florida Health/Shands Hospital

**EDUCATION**

 1978 B.S.-State University of New York at Stony Brook

 1982 M.D.-Columbia University College of Physicians and Surgeons, New York, New York

1. Certificate-Executive Program for Scientists and Engineers

Kellogg School of Management, Northwestern University

**POSTDOCTORAL TRAINING**

 1982-1985 Resident in Internal Medicine

 Beth Israel Hospital

 Harvard Medical School, Boston, MA

 1985-1988 Fellow in Medical Oncology, Dana-Farber Cancer Institute

 Harvard Medical School, Boston, MA

 1986-1991 Postdoctoral Fellow- Eukaryotic Transcription

 Dana-Farber Cancer Institute

 Harvard Medical School, Boston, MA

**LICENSURE AND CERTIFICATION:**

 1982 Massachusetts License Registration #52883

 1985 Diplomate, American Board of Internal Medicine

 1987 Diplomate, American Board of Internal Medicine

 Subspecialty-Medical Oncology #101083

 1992 New York State License Registration #187636-1 (Inactive)

 2006 Illinois License #36116430 (Inactive)

 2016 Florida License #ME126669 (Active)

**AWARDS AND HONORS**

 1978 Summa Cum Laude, SUNY Stony Brook

 1978 Phi Beta Kappa

 1982 Alpha Omega Alpha

 1996 Distinguished Research Award, Department of Medicine

 Mount Sinai School of Medicine

 1997 Committee of 1000 Outstanding Faculty Achievement

 Award in Basic Research, Mount Sinai School of Medicine

 2002 Burroughs-Wellcome Fund Clinical Scientist Award in

 Translational Research

 2007 Leukemia and Lymphoma Society Specialized Center of Research Excellence Award

 2010 Leukemia and Lymphoma Society Illinois Researcher of the Year

1. Best Basic Science Manuscript of the Year, Department of Medicine, Northwestern University Feinberg School of Medicine

 2015 Mentor of the Year

 Northwestern University Feinberg School of Medicine

 2021 American Society of Hematology Mentor Award- Basic Science

**OTHER PROFESSIONAL APPOINTMENTS**

*Professional Societies*

1. American Society of Hematology
2. American Society of Clinical Oncology
3. American Association for Cancer Research

2019 American Society for Biochemistry and Molecular Biology

2017 American Association for the Advancement of Science

## Honorary Professional Societies

1. American Society for Clinical Investigation

2005 Association of American Physicians

2017 American Clinical and Climatological Association

2020 Academy of Science, Engineering and Medicine of Florida

## Administrative Positions

 1997 Coordinating Reviewer, Oncogene Section

 American Society of Hematology Annual Meeting

 1998 Reviewer-Hematopoiesis Section

 American Society of Hematology Annual Meeting

 2000- Reviewer-Oncogenes Section

 American Society of Hematology Annual Meeting

 1997-2001 Subcommittee on Myeloid Biology

 American Society of Hematology

 1998-2000 Program Committee Tumor Biology and Molecular Genetics American Society of Clinical Oncology Annual Meeting

 1999 Contributor-ASCO Curriculum in Genetics

 2001 Chairperson, Subcommittee on Myeloid Biology

 American Society of Hematology

 2002 Reviewer-Leukemia Biology/Prognostic Markers Section

 American Society of Hematology Annual Meeting

 2004 Reviewer- Oncogenes Section

 American Society of Hematology Annual Meeting

 2005 Coordinating Reviewer-Oncogenes and Tumor Suppressors

 American Society of Hematology

 2005-6 Program Committee 2006 AACR Meeting

 2005-6 Chairman, Educational Committee 2006 AACR Meeting

 2005 Organizing Committee, Cancer and Signaling Group

 NY Academy of Sciences

 2005-7 Councilor, American Society for Clinical Investigation

 2008 Coordinating Reviewer-Leukemia Biology

 American Society of Hematology

 2010 Reviewer- Myeloproliferative Neoplasms Section

 American Society of Hematology Annual Meeting

 2011-12 Program Committee 2012 AACR Meeting

 2011-12 Co-Chair Education Committee 2012 AACR Meeting

 2013-2017 Councilor, American Society of Hematology

 2015-2017 Committee on Quality, American Society of Hematology

 2014-2015 Exhibits Committee, AACR Annual Meeting

 2014-2017 Publications Committee, AACR

 2015- Chair, AACR Taskforce on Hematological Malignancies

 2017 Co-Chair, ASH/EHA Translational Research Training in Hematology

 2019 Honorific Nomination Committee- AACR

 2019 Abstract Reviewer, Myeloma Section

 American Society of Hematology Annual Meeting

## Editorial Boards

 1998-2008 Editorial Board-*Leukemia*

 2000-2004 Editorial Board-*Blood*

2001-2021 Associate Editor-*Cancer Biology and Therapy*

2001-2008 Section Editor-*Leukemia*

2002-2008 Editorial Board-*Nucleic Acids Research*

2003-2009 Associate Editor-*Cancer Research*

 2004-2009 Editorial Board*- Stem Cells*

 2004-2009 Consulting Editor, *Journal of Clinical Investigation*

 2006-2016 Senior Editor- *Clinical Cancer Research*

 2009-2016 Editorial Board-*Oncogene*

 2012-2020 Editorial Board-*Cancer Cell*

 2010-2020 Editorial Board, *Clinical Epigenetics*

2011- Editorial Board-*Cancer Today*

 2016- Editorial Board-*Cancer Research*

 2016- Associate Editor-*Oncogene*

2019- Editorial Board-*Blood Cancer Discovery* 2020- Scientific Editor-*Cancer Discovery*

 2020- Associate Editor, *Clinical Epigenetics*

*Manuscript Review*

ACS Chemical Biology

American Journal of Pathology

BBA Gene Regulation

BBA Reviews in Cancer

Biochemie

Biochemistry and Cell Biology

BioMed Research International-Pharmacology

Biomaterials

Blood

Blood Advances

Blood Cancer Discovery

Blood Cells Molecules and Disease

BMC Cancer

British Journal of Cancer

Cancers

Cancer Cell

Cancer Communications

Cancer Discovery

Cancer Investigator

Cancer Management and Research

Cancer Research

Cell

Cell & Bioscience

Cell Cycle

Cell Death and Differentiation

Cell Death and Disease

Cell Growth and Differentiation

Cell Reports

Cell Stem Cell

Cellular & Molecular Biology Letters

Chemistry & Biology

Chemico-Biological Interactions

Clinical Epigenetics

Clinical Lymphoma, Myeloma and Leukemia

Current Protein & Peptide Science

Communications Biology

Complexus

Development

Developmental Biology

Developmental Cell

Disease Markers

eLife

EMBO Molecular Medicine

Endocrine Related Cancer

Epigenetics and Chromatin

Epigenomics

European Journal of Hematology

European Journal of Pharmaceutical Sciences

Experimental Hematology

Frontiers in Cancer Genetics

Gene

Genes and Development

Gene Expression Patterns

Genes to Cells

Hematologica

Hippocampus

Human Molecular Genetics

International Journal of Laboratory Hematology

Journal of the American Medical Association

Journal of the American Society of Nephrology

Journal of Biological Chemistry

Journal of Biotechnology

Journal of Cell Physiology

Journal of Clinical Epidemiology

Journal of Clinical Oncology

Journal of Experimental Medicine

Journal of Molecular Biology

Journal of Neuroscience

Journal of Precision Oncology

Leukemia

Leukemia and Lymphoma

Leukemia Research

Mechanisms of Development

Molecular Cancer

Molecular Cancer Research

Molecular Cancer Therapeutics

Molecular Cell

Molecular and Cellular Biology

Molecular Pharmacology

Mutation Research

Nature

Nature Cancer

Nature Chemical Biology

Nature Communications

Nature Genetics

Nature Medicine

Nature Reviews Cancer

Neoplasia

Neuroscience Research

New England Journal of Medicine

NPJ Precision Oncology

Nucleus

Oncogene

Oncotarget

Oncotargets and Therapy

Physiological Genomics

PLoS Biology

PLoS Computational Biology

PLoS Genetics

PLoS One

Proceedings of the National Academy of Sciences

Proceedings of the Society for Experimental Biology And Medicine

Science

Science Advances

Science Translational Medicine

Scientific Reports

Seminars in Cancer Biology

The Lancet

Therapeutic Advances in Hematology

Trends in Biochemical Science

Trends in Genetics

Trends in Immunology

Wiley Interdisciplinary Reviews: Systems Biology and Medicine

## Grant Review

 1994, 5 Site visitor NIDDK PO1 Grant- U. Of Pennsylvania

 1995 NCI Conference Grant Reviewer for

 1995-6 Ad Hoc Member, Drug Development, Hematology and Pathology

 Advisory Board, American Cancer Society

 1995 Grant Reviewer, Diabetes Center,

 Washington University School of Medicine

 1996 Grant Reviewer, VA Merit Program

 1997-2000 Member- Leukemia and Blood Cell Biology Advisory Board

 American Cancer Society (Four-year term)

 1997 Program Project Grant Evaluator- NIAID-Univ. of Illinois

 1998 Epidemiology and Disease Control, Special Emphasis Panel- NIH

 1998 Site Visitor for NCI PO1 Grant- MD Anderson Cancer Center

 1998-2001 Ad Hoc Member, Pathology B Study Section- NIH

1999, 2002, 2004 Israel Cancer Research Fund

2000 Site Visitor for NCI PO1 Grant-Salk Institute

 2000, 2001 Ad Hoc Reviewer, Netherlands Cancer Organization

 2001- Ad Hoc Reviewer- Wellcome Trust

 2001- Lauri Strauss Leukemia Foundation

* 1. Leukemia and Lymphoma Society- SCOR Review Panel

 2001-2006 Member-Cancer Molecular Pathology Study Section-NIH

 2002 Ad Hoc Reviewer-National Science Foundation

 2002 American Society of Hematology Scholar Awards

 2003 Ad Hoc Member-NIDDK Board of Scientific Counselors

2006 Multiple Myeloma Research Foundation

 2007 Ad Hoc NCI PO1 Review Committee

 2008-9 Reviewer -Comprehensive Cancer Center Program

 Deutsche Krebshilfe, Germany

 2008-10 Ad Hoc Reviewer Kay Kendal Leukemia Research Foundation

 2009 Ad Hoc reviewer, Intramural Program, National Cancer Institute

 2009 Ad Hoc Member-Cancer Molecular Pathology-NIH

 2009 Chair, AACR Fellowship Review Committee

 2009- Multiple Myeloma Research Foundation

 2009-2014 Board of Scientific Counselors, National Cancer Institute

 2010, 2013 Ad Hoc Reviewer, Austrian Science Fund

 2011, 2012, 2015 Myeloproliferative Neoplasm Foundation

 2011 Ad Hoc Reviewer, Deutsche Krebshilfe, Germany

 2011 Pilot Project Reviewer

 Washington University, Siteman Cancer Center

 2012 Site Visitor, Comprehensive Cancer Center Program

 Deutsche Krebshilfe, Germany

 2012-2016 Chair, LLS SCOR Review Committee

 2013, 2014 ASH Scholar Awards Review Committee

 2013, 2015 Italian Ministry of Health Grants reviewer

 2014 Site Visitor, Comprehensive Cancer Center Program

 Deutsche Krebshilfe, Germany

 2014 Chair, LLS Quest for Cures Review Committee

 2014 Site Visitor, Cancer Research UK

 2014 Ad Hoc Reviewer-Terry Fox Cancer Research Center

 2014 Ad Hoc Reviewer-International Myeloma Foundation

 2014 Ad Hoc Reviewer-Leukemia and Lymphoma Research, UK

 2015 Ad Hoc Member-Basic Mechanisms of Cancer Therapeutics Study Section-NIH

 2015 Ad Hoc Reviewer-Cancer Research, UK

 2015 Ad Hoc Reviewer-Israel Science Foundation

 2015 Ad Hoc Reviewer-Swiss Cancer League

 2015 Ad Hoc Reviewer-Netherlands Organization for Scientific Research

 2015 Ad Hoc Reviewer-Research Councils UK

 2015-2017 Member-Basic Mechanisms of Cancer Therapeutics

 Study Section–NIH

 2015 Site Visitor, Stanford Cancer Center Support Grant Review

 2016 Site Visitor, U Nebraska Cancer Center Support Grant Review

 2016 Site Visitor, Emory University Cancer Center Support Grant Review

 2016-2017 AACR NextGen Grants Review Panel

 2016 Chair-International Review Committee

 Pan-Canadian Translational Research Program

 Terry Fox Research Institute, Toronto, CA

 2017 Site Visitor, Oklahoma University Cancer Center Support Grant Review

 2017-2019 Chair-Basic Mechanisms of Cancer Therapeutics

 Study Section–NIH

 2018 Ad Hoc Reviewer, Emerson Collective, Columbia University

 2018, 2019 Site visitor, LLS SCOR program

 2020 Reviewer-Comprehensive Cancer Center Program

 Deutsche Krebshilfe, Germany

 2020 Reviewer - Wellcome Trust DBT India Alliance Fellowship

 2020 State of Ohio Grants Program

 2020 Multiple Myeloma Research Foundation

 2020 Melanoma Research Foundation

 2020 AACR Next Generation Awards

 2020 NIH Special Emphasis Panel

 2021 Site Visitor, Kimmel Cancer Center, Johns Hopkins

 Cancer Center Support Grant

 2022 Edward P. Evans MDS Foundation

 2022 LLS SCOR Review Panel

 2022 NCI R50 Clinical Research Specialist Review

## Mount Sinai Administrative Positions

 1992- Member-Graduate School of Biological Sciences

 Mount Sinai School of Medicine, New York, NY

 1993-2005 Assistant Director, Medical Scientist Training Program

 Mount Sinai School of Medicine

 1997-2002 Director-Research Education, Department of Medicine

 Mount Sinai School of Medicine

 2000-2002 Associate Director for Translational Research

 Derald H. Ruttenberg Cancer Center

 Mount Sinai School of Medicine

 2002-2004 Vice Chairman for Research

 Department of Medicine

 Mount Sinai School of Medicine

 2003-2005 Chief-Division of Hematology/Oncology

 Department of Medicine

 Mount Sinai School of Medicine

 2004-2005 Associate Dean for Cancer Programs

 Mount Sinai School of Medicine

## Northwestern University Administrative Positions

 2006-2015 Chief-Division of Hematology/Oncology

 Department of Medicine

 Northwestern University

 Feinberg School of Medicine

 2006-2015 Associate Director for Clinical Sciences

 Robert H. Lurie Comprehensive Cancer Center of

 Northwestern University

 2011-2013 At Large Director- Northwestern Medical Faculty Foundation

 2014-2015 Director- Oncology, Northwestern Medical Group

## University of Florida Administrative Positions

 2015- Director, UF Health Cancer Center

 2020- Board of Trustees, University of Florida Proton Therapy Institute

 2022- Associate Vice President Cancer Services, UF Health

 2022- Member, Board of Directors, UF Health Shands

## Mount Sinai Intramural Committees

 1996 Department of Medicine New Faculty Search Committee

 1996 Pulmonary Division Chief Search Committee

1996-2005 Department of Medicine Research Day Committee

 1996 NYU-Mount Sinai Merger Talks-Graduate School

 1997-2003 Chair, Department of Medicine Research Day

 1997 Mount Sinai Breast Cancer Resource Advisory Board

 1997-2005 Admissions Committee-MSTP Program

 1997-2005 Dean’s Committee on Ethical Practices in Research

 1998 Committee on Core Facilities

 1998 Mini-Medical School Committee

 1998 Selectives Subcommittee-Curriculum 2000

 1999 Cancer Center Committee Core Facilities

 1999-2001 Cancer Center Working Group-Hematological Oncology

 1999-2001 Dean’s Committee on Grants and Fellowships

 1999-2005 Medical Scientist Training Program Steering Committee

 1999 Dean’s Committee on Special Teaching Awards

 1999-2001 Cancer Center Protocol Review Committee

 2000-2002 Cancer Center Steering Committee

 2001 Intramural Review Committee-Department of Obstetrics and

 Gynecology

 2002 Chair Search Committee- Clinical Oncology Leader

 2002 Faculty Advisory Council -HRSA Center of Excellence for Minority Faculty Recruitment and Development

 2003 LCME Group on Research Education

 2005 Intramural Departmental Review Committee

## Northwestern University Feinberg School of Medicine Intramural Committees

 2006 Internal Advisory Committee- GI Oncology SPORE Grant

 2006 Renal Division Chief Search committee

 2006- Lurie Cancer Center Executive Committee

 2006-7 Feinberg School of Medicine Research Council

2007 Search Committee- Psychiatry Chair

2007-2012 Appointments Promotions and Tenure Committee

1. Selection Committee, Director -Integrated Graduate Program

2008-2012 Senior Faculty Advisory Committee

1. Taskforce on Promotions and Tenure

2009 Cancer Genetics Program Leader Search Committee

2010 Prostate Cancer Research Director Search Committee

2010-2015 NU Prostate Cancer SPORE, Internal Advisory Committee

2010-2015 NU GI Cancer SPORE, Internal Advisory Committee

2011-2015 Department of Medicine Research Council

2011-2013 Board of Directors, Northwestern Medical Faculty Foundation

2013-2014 Pediatric Oncology Chief Search Committee

2014-2015 Pediatrics Chair Search Committee

2014-2015 Biochemistry and Molecular Genetics Faculty Search Committee

2015 NU Leukemia SPORE, Internal Advisory Committee

## The University of Florida Intramural Committees

2017 Chemistry Department Search Committee

2017-18 Department of Pathology Physician Scientist Search Committee

 2018 Chair, Department of Medicine Chair Search Committee

 2019-2020 Member, Department of Medicine Hematology/Oncology Division Chief Search Committee

## Other Extramural Committees

1996-2005Scientific Advisory Board, The Chemotherapy Foundation

 1997 Co-Chair, Group on Susceptibility Factors, U.S. EPA Conference on Preventable Causes Of Cancer In Children

 1997-1998 Co-Chair for Molecular Biology, Leukemia Committee-Eastern Eastern Cooperative Oncology Group

 1999-2000 Scientific Advisory Board, Intergen Company

 2001 Chairperson-American Society of Hematology

 Subcommittee on Myeloid Biology

 2001-2019 Associate Scientific Director,

 Samuel Waxman Cancer Research Foundation

 2003-2005 Scientific Advisory Board- Kalypsys, Inc.

 San Diego, CA

 2004-2008 Scientific Advisory Board

 Phylogica, Perth Australia

 2004-2005 Extramural Scientific Advisor, U Penn PO1 on Melanoma

* 1. Nominating Committee, American Society of Hematology

2007 Leukemia Committee-Eastern Cooperative Oncology Group

 2008 Extramural Advisor Washington University Leukemia SCOR

1. Extramural Scientific Advisor, Ohio State University PO1

2008 Awards Committee, AACR

2008-2013 Scientific Advisory Board

 Myeloproliferative Disease/Neoplasm Foundation

2009-2012 Finance Committee, American Society of Hematology

1. Chair- Fellowship Awards Committee,

American Association for Cancer Research

2009 Extramural Scientific Advisor, Washington University PO1

2009- Translational Research Committee

 American Association for Cancer Research

2010, 11 Extramural Scientific Advisor, Cornell University PO1

2011- Extramural Scientific Advisor, Washington University SPORE

2013- Medical Scientific Board, Leukemia and Lymphoma Society

2013-2017 ASH/EHA Translational Research Training in Hematology Joint Oversight Committee

2013- 2015 External Advisory Board, ECOG/ACRN Leukemia Laboratory Committee

2015-2016 External Advisory Board, University of Arkansas Myeloma PO1

2015- Chairperson, Taskforce on Hematological Malignancies, AACR

2016- External Advisory Board

 Siteman Cancer Center, Washington University, St. Louis

2016 Scientific Advisory Committee

 Genetics Branch, Center for Cancer Research, NCI

2017- External Advisory Board

 NYU Leukemia P01

2020- Chief Scientific Advisor- Samuel Waxman Cancer Research Foundation

2021 Co-chair- Medical Scientific Board

 Leukemia and Lymphoma Society

## Conference Organization

 1997 Session Chair, Acute Promyelocytic Leukemia

 1997 FASEB Conference on Hematological Malignancies

 1997-1999 Chairman, 1999 FASEB Conference on

 Hematological Malignancies

 1998-2014 Session Organizer- Myeloid Meeting at the American Society of Hematology Meeting

 2005-2006, 2007 Program Committee Member, AACR Annual Meeting

 2005-2006 Chairman, Educational Committee, AACR 2006 Annual Meeting

* 1. Co-Chair, International Conference on Differentiation Therapy
	2. Program Committee Member, AACR Annual Meeting

Co-Chair- Educational Committee, AACR Annual Meeting

2012-2013 Program Committee Member, AACR Annual Meeting

2013-2014 Program Committee Member, AACR Special Meeting on Hematological Malignancies

 2015-2017 Vice-Chair, Gordon Conference on Cancer Genetics and Epigenetics

2016-2017 Program Committee Member, AACR Annual Meeting

2016-2017 Chair, AACR Meeting on Hematological Malignancies

 2017-2019 Chair, Gordon Conference on Cancer Genetics and Epigenetics

**Training Record**

Past Trainees:

Graduate Students

 Josina C. Reddy, MD, Ph.D.-1993-1995

Currently Position-Clinical Scientist- Genentech, San Francisco, CA

 Odelia Lee M.S.NYU-1996. Most recently Ph.D. Student, Albert Einstein College of Medicine

 Jia-Yuan Li, Ph.D.-1993-1997

Currently Position-Manager of Medical Information and Publications

Genentech, South San Francisco, CA

Rita Shaknovich, MD, Ph.D.- 1993-1997

Currently Position-Assistant Professor, Pathology

Weill Cornell College of Medicine, New York Greg Holmes, Ph.D.- Visiting student, Winter 1995.

Currently Position-Instructor, Mount Sinai School of Medicine

Yariv Houvras, MD, Ph.D.-1996-1999- Graduated MSSM 2001

Postdoctoral fellow-Laboratory of Dr. Len Zon, Harvard Medical School

Currently Position-Regeneron Pharmaceuticals, Tarrytown, NY

Milton English, Ph.D. 1995-2001

Currently Staff Scientist, National Eye Institute

 Windy Berkofsky-Fessler , Ph.D. 2002-2006

 Currently Research Scientist, Roche Laboratories, Nutley, NJ

 Simge Akbulut Ph.D. Mount Sinai School of Medicine 2002-2007

 Jotin Marango, M.D., Ph.D. Mount Sinai School of Medicine 2003-2007, M.D. 2009.

 Currently, Founder-Schroedinger Consulting Group, New York, NY

 Xiaoxing Lin, PhD. 2007-2012

 Recipient of the Malkin Scholarship

 Current Position- LEK Consulting Boston, MA

 Behnam Nabet, PhD 2010-2015

 Training grant awardee - Cellular and Molecular Sciences, Northwestern University

 Currently Position- Assistant Professor, Fred Hutch Cancer Research Center, Seattle, WA

 Alok Swaroop MD, Ph.D.-2013-2019

 Training Grant Awardee- Carcinogenesis, Northwestern University

 F30 Award, National Cancer Institute

 Current Position- Heme/Onc Fellow, Northwestern Memorial Hospital

 Xiaoxiao Huang, Ph.D. 2013-2019

 Current Position- Research scientist- Regeneron, Inc.

Postdoctoral fellows

 Patricia Yeyati, Ph.D. 1995-1998

 Currently Position-Staff Scientist-MRC Edinburgh

 Scotland, UK

 Cheryl Lempert, M.D.- 1996-1997

 Current Position: Pediatric Oncologist

 Irvine, CA

 Sally Arai, M.D. Heme/Onc Fellow- 1998-1999

Currently Position: Associate Professor Of Medicine (Blood And Marrow Transplantation)

Stanford University Medical Center, Palo Alto, CA

 Helen Ball, Ph.D.-1996-1999

 Rolf Edgar Lake Fellow, Pathology, School of Medical Sciences

 Sydney University, Australia

 Seiyu Hosono, Ph.D.-1995-2000

 Current Position: Principal Scientist, Miltenyi Biotec

 Waltham, MA

 Ari Melnick, M.D.- 1996-2002 (K08 Recipient, 2001 ASH Scholar Award)

 Current Position: Laurel Gebroe Family Professor of Hematology/Oncology

 Division of Hematology/Oncology, Weill Cornell College of Medicine

 New York, NY

 Isabelle Gross, Ph.D.- 1997-2002

 Recipient of French Association of Cancer Research Fellowship

 Current Position: INSERM Permanent Scientist

 Strasbourg, France

 Albert Basson, Ph.D.-2000-2002

Recipient of a Wellcome Trust Fellowship

Current Position: Professor of Developmental Neurobiology

MRC Centre for Neurodevelopmental Disorders

King's College London, UK

 Nathalie Chevalier, Ph.D.2000-2003

 Current Position: Institut Mondor de Recherche Biomédicale

 INSERM U955, Paris, France

 Shinchiro Takahashi, M.D., Ph.D. 2001-2003

 Current Position: Professor

 Tohoku Medical and Pharmaceutical University

 Sendei, Japan

 Andreas Sirulnik, M.D., Ph.D-Hematology/Oncology Fellow 2002-2003

 Recipient of CALGB Junior Investigator Award

 Recipient of Multiple Myeloma Research Foundation Fellowship

 Currently Position: Senior Vice President Regeneron Pharmaceuticals, Tarrytown, NY

 Miriam Benezra, Ph.D.1999-2003 Current Position: Research Scientist

 Memorial Sloan Kettering Cancer Center, New York, NY

 Jacqueline Mason, Ph.D.-2002-2006

 Recipient of a Revson Fellowship

 Current Position: Staff Scientist, Campbell Family Institute for Breast Cancer Research

 Princess Margaret Hospital, Toronto, CA

 Manabu Shimoyama, M.D.-2003-2006

 Recipient of Lauri Strauss Leukemia Foundation Fellowship

 Current Position: Staff Physician, Department of Hematology/Oncology

 Kobe University, Japan

 Melanie McConnell, Ph.D.-1998-2003

 Current Position: Senior Lecturer, Biological Sciences

 Victoria University of Wellington, NZ

 Vivenne Ambruster, PhD 2005-2006

 Current Position: Postdoctoral Fellow, Germany

Deborah Morrison. Ph.D.- 1998-2006

Selected for a renal research training grant position, Mount Sinai School of Medicine

Recipient of America Urological Association Research Award

 Current Position: Research Assistant Professor- New York University

 Tomas Villas, PhD 2006-2007

 Current Position: Research Staff Scientist, NCI Frederick

 Monica Buzzai, Ph.D. 2006-8

 Recipient of Fellowship from the Lori Strauss Leukemia Foundation

 American/Italian Cancer Foundation Fellowship

 Current Position: Leader, Novartis Oncology, Milan, Italy

 Itsaso Hormanche, Ph.D.-2004-8

 Recipient of Fellowship from the Basque Government

 Current Position: Biotech

 Bilbao, Spain

 Marianne Kim, Ph.D.-2004-2008

 Recipient of an American Cancer Society Postdoctoral Fellowship

 Current Position: Director of Research and Development

 BioFire Defense, Salt Lake City

 Kim Rice, PhD- 2004-2009 Recipient of Fellowship from the Leukemia Research Foundation

 Current Position: Director Pipeline Development, PYC Therapeutics

 Perth, Australia

 Pallavi Chaturverdi, PhD 2009

 Current Position: Research Scientist

 HCW Biologics, Miramar, FL

 Eva Martinez, Ph.D. 2007-2012

 Recipient of MMRF and European Hematology Association Fellowship

 Current Position: Head of Quality Control, Biological Laboratory at 3P Biopharmaceuticals

 Pamploma, Spain

 Kristy Wolniak, MD, PhD.-2009-2013

 Recipient of Individual NRSA

 Current Position: Associate Professor of Pathology

 Northwestern University Feinberg School of Medicine

 Zheng Zhou, MD, PhD 2012- 2014

 Northwestern Hematology Oncology Fellow

 Current Position: Hematology/Oncology Lahey Clinic,

 Relja Popovic, PhD 2008-2014

 Recipient of T32 Funding, individual NRSA and MMRF Fellowship

 Current Position: Group Leader, Abbvie, North Chicago, IL

 Teresa Ezponda, Ph.D. 2010-2015

 Recipient of Alfonso Martin Escudero Fellowship, Spain

 Current Position: Scientist, University of Navarra, Pamploma, Spain

 Eliza Small, Ph.D. 2012-2015

 Recipient of individual NRSA

 Current Position: Scientist Epigenetic Targets, Thermo Scientific, Rockford, IL

 Jon Oyer, PhD. 2012-2015

 Recipient of Chicago Biomedical Consortium Postdoctoral Fellowship

 Lauri Strauss Leukemia Foundation Fellowship

 Current Position: Senior Principal Scientist, Pfizer, San Diego, CA

 Kelly Arcipowsky, Ph.D. 2013-2015

 Training Grant Awardee- Signaling and Cancer, Northwestern University

 Current Position: Senior Scientist at Pfizer - Clinical Biomarker Technologies, Groton, CT

 Mrinal Shah, Ph.D. 2010-2016

 Current Position: Scientific Writer

 Abbvie, North Chicago, IL

 Catalina Troche, Ph.D. 2016-2017

 Current position, Senior Scientist, Curtiss Healthcare

 Gainesville, Florida

 Adiyta Bele, Ph.D. 2016-2018

 Camille Jacques, PhD. 2017-2018

 Mohamad Alizrigat, PhD- 2017-2018

 Recipient of AACR- LOXO Pediatric Cancer Research Fellowship

 Sayantan Maji, Ph.D. 2016-2019

 Current Position- Postdoctoral Fellow- The University of Pennsylvania

Current Trainees:

Graduate Students

 Gabriel Prado 2018-

 Charlotte Kaestner 2019-

 Kimberley Pereira 2020-2022

Postdoctoral fellows

 Daphné Dupéré-Richer, Ph.D. 2016-

 Leukemia and Lymphoma Society Special Fellow Award

 Jianping Li, MD. 2017-

 Leukemia and Lymphoma Society Special Fellow Award

 Amin Sobh, PhD, 2018-

 Recipient of AACR Postdoctoral Fellowship on Myeloma

 Leukemia and Lymphoma Society Special Fellow Award

**TEACHING ACTIVITIES**

**Graduate school- Mount Sinai School of Medicine**

1992 Advanced Molecular Biology Course- Oncogenes and Tumor Suppressor Genes-8 sessions

1993-4 Molecular and Cellular Biology Core II-5 lectures each term

1993 Course Director, Molecular Biology Section of Core I- DNA Structure and Transcription Transcriptional Regulation-six lectures and supervised course

1994-97 Molecular and Cellular Biology Core I

 Lectures on Transcriptional Regulation in Prokaryotes and Eukaryotes- six lectures each fall

1995-96 Course Co-Director, Tumor Suppressor Section of Cancer Biology-8 small group sessions

1997-2000 Instructor-Cancer Biology Section, Molecular Basis of Disease Course-2 hours each spring

1998 Course Co-Director, Advanced Cancer Biology -Novel Tumor Suppressor Genes-

 10 small group sessions

2000 Advanced Cancer Biology Course, The Ras Oncogene- 10 small group sessions

2002 Molecular basis of Disease- Lectures on Transcription Factors in Cancer

1992- Thesis Advisor

 Josina Reddy (M.D./ Ph.D.) (1992-1995)

 Jia Li (Ph.D.) (1992-1997)

 Rita Shaknovich (M.D./Ph.D.) (1993-1997)

 Yariv Houvras (M.D./Ph.D.) (1995-1999)

 Milton English (Ph.D.) (1995-2001)

 Windy Berkofsky-Fessler (Ph.D.) (2002-2006)

 Simge Akblut (Ph.D.) (2002-2007)

 Jotin Marango (Ph.D.) (2003-2006)

##### Thesis Committees

Thesis Defense Committee- Ira J Miller, Mount Sinai School of Medicine, 1994

Outside Thesis Reviewer- Wendy Bruening, McGill University 1997

Thesis Defense Committee- Sunyung Kim, Mount Sinai School of Medicine, 1998

Thesis Defense Committee-Vladamir Bodganov, Mount Sinai School of Medicine, 1998

Thesis Defense Committee-Aza Idris, Mount Sinai School of Medicine, 1999

Outside Thesis Reviewer-Nathan Lawson, Yale University School of Medicine, 1999

Outside Thesis Reviewer- Edmund Sim, University of Queensland, Australia, 2000

Thesis Defense Committee-Jeremy Ward, Cornell University Medical College, 2000

Thesis Defense Committee- Jessica Feinlieb, Mount Sinai School of Medicine, 2000

Thesis Defense Committee- Ed Thornborrow, Mount Sinai School of Medicine, 2001

Outside Thesis Reviewer- Jennifer Best, Harvard Medical School, 2001

Thesis Defense Committee-Keon Menzies, Mount Sinai School of Medicine, 2001

Outside Thesis Reviewer- Thomas Bush, Brown University, 2002

Visiting Thesis Reviewer, Heather Andrews, Queens University Belfast, 2003

Chair, Thesis Committee-Marianne Kim, Mount Sinai School of Medicine, 2003

Thesis Committee-Alex Kentsis, Mount Sinai School of Medicine, 2004

Thesis Committee-Timothy Bowler, Mount Sinai School of Medicine, 2004

Thesis Committee-Wei Zhang, Mount Sinai School of Medicine, 2005

Thesis Committee-Ina Nusinzon, Mount Sinai School of Medicine, 2006

Thesis Advisory and Defense Committee-Mrinal Shah, University of Chicago, 2007-2010

Thesis Advisory and Defense Committee-Mandy Redig, Northwestern University, 2006-2009

Thesis Advisory and Defense Committee-Rhonda Brown, Northwestern University, 2008-2011

Thesis Advisory and Defense Committee. Maya Srikanth-Northwestern University, 2008-2012

Thesis Advisory and Defense Committee, Louis Doré-Northwestern University, 2009-2012

Thesis Advisory and Defense Committee. Jessica Shulte-Northwestern University, 2009-2012

Thesis Advisory and Defense Committee. Anaar Silentz-Northwestern University, 2010-2012

Thesis Advisory and Defense Committee. Ben Goldenson-Northwestern University, 2011-2014

Thesis Advisory and Defense Committee. Jessica Huszar-Northwestern University, 2011-2014

Thesis Advisory Committee. Craig Smuda-Northwestern University, 2010-2013

Thesis Advisory and Defense Committee- Jenny Kerschner- Northwestern University, 2010-2013

Thesis Advisory Committee. Andrea Glausner-Northwestern University, 2010-2013

Thesis Advisory and Defense Committee. Jennifer Heller-Northwestern University, 2010-2014

Thesis Examiner- Van Andel Institute, Grand Rapids, MI, 2012

Opposition Thesis Examiner- Karolinska Institute, Sweden, 2012

Thesis Advisory and Defense Committee - Suzanne Wetz- Northwestern University, 2012-2017

Thesis Advisory and Defense Committee. Jung Kim-Northwestern University, 2012-2015

Outside Thesis Reader- Mohsen Ghahremanlou- U Toronto, 2013

Thesis Examiner-Aurora Negro, Oespdale San Rafaelle, Milan, 2013.

Thesis Advisory Committee. Angela Yang-Northwestern University, 2013-2017

Thesis Advisory and Defense Committee. Andrea Calver- Northwestern University, 2013-2017

Thesis Advisory and Defense Committee. Sali Liu- Northwestern University, 2013-2017

Thesis Advisory Committee. Daniel Levine-Northwestern University, 2013-2015

Thesis Advisory Committee. Johanna Melo Cardenas-Northwestern University, 2014-2018

Outside Thesis Examiner, Ankit Dutta, The University of Adelaide, Australia - 2018

**Graduate school- Northwestern University**

2006-2009 Integrated Graduate Program- Molecular Biology Seminar Course

2014-2015 Lecturer, Cancer Biology Course

2007-2015 Thesis Advisor

 Xiaoqin Lin (Ph.D.) (2007-2012)

 Behnam Nabet (Ph.D.) (2010-2015)

 Alok Swaroop (Ph.D. (2013-2018)

 Xiaoxiao Huang (Ph.D.) (2013-2019)

**Graduate school- University of Florida**

Thesis Advisory Committee. Keith Christopher- University of Florida, 2016

Thesis Advisory Committee. Andrew Tamashunas- University of Florida, 2016-2019

Thesis Advisory Committee. Julie Bray- University of Florida, 2016-2019

Thesis Advisory Committee. Kartika Venugopal - University of Florida, 2017-2020

Thesis Advisory Committee. Yang Feng - University of Florida, 2018-

Thesis Advisor

 Gabriel Prado (2018-)

 Charlotte Kaestner (2019-)

 Kimberly Pereira (2020-)

**Medical School- Mount Sinai**

1992-1997 Attending Physician on general medicine 1 month/year

1992-1997 Resident Report approximately 1x/month

1995-2005 Attending Physician Hematology Service-Weekend supervision of fellows in general hematological malignancy and bone marrow transplantation- 8 weekends/year

1996-2006 Lecturer, Second Year Pharmacology Course-Cancer Chemotherapy- 3 hours/yr

1996-2001 Lecturer, Second Year Pathophysiology-Renal Neoplasms-one hour each spring

1997-1999 Preceptor-Evidence Based Medicine Course- Third Year Medicine-2 sessions/year

1998-2005 Preceptor- Hematology Section, Second Year Pathophysiology Course

 10-12 small group sessions each year

2000-2005 Molecules and Cell Course- First Year Medical School- seven hours of lecture

* 1. Attending Physician- Hematological Malignancies Service 4 weeks/year

**Medical School- Northwestern University Feinberg School of Medicine**

2006-2015 Attending Physician- Hematological Malignancies 2-4 weeks/year

2014 Lecture- Transcriptional Deregulation in Cancer- M2 Hematology/Oncology Course

2014-2015 Monthly Chief of Service Rounds- Leukemia Service

**Active Grant Support**

R01DK121831 (Guryanova) 07/15/19-04/30/24

NIH/NIDDK $225,000

*The role of DNMT3A mutations in clonal heterogeneity and evolution of hematopoiesis*

We will study the evolution and competition among different stem cells in the blood system, termed clonal evolution, how this process leads to premalignant “clonal hematopoiesis”, and the mechanisms that drive it. By identifying molecular mechanisms whereby *DNMT3* mutations promote clonal evolution, this work will contribute to rational design of new treatments to prevent or delay progression of clonal hematopoiesis to myeloid malignancies.

Role: Co-Investigator

U01CA225566 (Lele) 03/06/20-02/28/25

NIH/NCI $49,799

*Nuclear Dysfunction in Cancer: The Role of Mechanical Stresses Transmitted by the LINC Complex*

Molecular linkers of the nucleus to the cytoskeleton transmit forces between the cell microenvironment and the genome. They are frequently mutated or dysregulated in cancer, and some of these changes have been proposed to be cancer drivers through unknown mechanisms. Here a multidisciplinary team will combine molecular biology, cell biology, and physical-science based approaches to address this fundamental question.

Role: Co-I

R01CA195732 (Licht) 08/11/16 – 7/31/22

NIH/NCI $225,000

*MMSET – The Role of MMSET in the Pathgenesis and Progression of Lymphoid Malignancy*

The goals of this project are Aim 1: To Determine Biological Activity of a Recurrent Point Mutation of MMSET in Malignancy. We will determine the mechanism of action of this protein in vitro and in vivo and how it alters histone methylation levels. Aim 2: Determine the Genetic Targets and Pathways Affected by Oncogenic Mutations of MMSET Preliminary data suggest that mutant MMSET activates a different set of genes in ALL compared to those Aim 3: Construct Animal Models of the Oncogenic Action of MMSET

Role: PI

7021-20 (Licht) 10/01/19-09/30/24

Leukemia and Lymphoma Society $833,333

Targeting Enhancer Dysfunction in Hematological Malignancy

This current proposal focuses on enhancer dysfunction in leukemia, lymphoma and myeloma due to alteration of the KDM6A/KMT2C/D complex that generally activates genes through chromatin modification and recruitment of other factors including remodeling enzymes.

Role: PI

LTR DTD 07-18-2019 (Licht) 07/01/2019-06/30/2021

Samuel Waxman Cancer Research Foundation $25,000

SWCRF Institute Without Walls

Dr. Licht is studying KDM6A, an enzyme that demethylates the H3K27me3 mark which is added by EZH2. He has found that KDM6A is a tumor suppressor, but it may be KDM6A’s scaffold function that is more important for its function as a tumor suppressor than its catalytic functions. He has also observed that KDM6A’s loss is associated with and cooperates with many oncogenes in cancer including K=ras. Thiswork is moving forward in a very positive manner.

Role: PI

21L05 (Licht) 5/11/21-4/30/24

Florida Department of Health $214,783

*NSD2 Mutation as Driver of Brain Invasion in Acute Lymphoblastic Leukemia*

Our hypothesis is that NSD2 drives expression of genes that stimulate cell growth and therapy resistance in childhood ALL as well as invasive aggressive behavior – we will identity the downstream genes responsible for this

Role: PI

22L03 (Licht) 4/1/22-3/31/25

Florida Department of Health $217,391

*Elucidation and targeting of epigenetic changes resulting in glucocorticoid resistance in pediatric acute lymphoblastic leukemia*

Glucocorticoids (GC) are a major component of therapy of pediatric acute lymphoblastic leukemia (ALL). Early relapse of ALL is associated with mutations/deletion of NR3C1 (glucocorticoid receptor, GR), NR3C2 (mineralocorticoid receptorMR) and NSD2 (histone methyltransferase). We hypothesize that these mutations affect therapeutic response to GC. GR and MR both bind GC and enter the nucleus to alter gene expression. Both proteins may mediate the therapeutic effect of GC in ALL.

Role: PI

22B10 (Licht) 4/1/22-3/31/25

Florida Department of Health $498,261

*Mitochondrial modulators of multiple myeloma growth and therapy resistance*

We hypothesize that MM growth depends on mitochondria energy production and AK2 to prevent ER stress, representing a therapeutic vulnerability

Role: PI

AGR00020252 (Licht) 7/15/21-7/14/22

Epizyme $89,851

*The mechanism of SETD2 inhibitors in NSD2 Mutant Blood Malignancies*

We will test these ideas in the following specific Aims:

Aim 1- Determine whether NSD2 overexpression or gain of function mutations increase sensitivity to SETD2 inhibitors using isogenic gene edited cells lines; Aim 2- Determine the epigenetic consequences of SETD2 inhibition in MM, ALL and MCL cell lines; Aim 3 – Determine genetic factors that modulate sensitivity to SETD2 inhibitors

R01CA256193 (Smalley) 8/9/21-7/31/26

NIH/NCI $201,236

*Characterization and targeting of the epigenetic state underlying uveal melanoma liver metastasis*

Uveal melanoma (UM) is a highly aggressive and frequently fatal cancer of the eye that metastasizes to the liver. The goal of this proposed study is to define the mechanisms underlying UM liver metastasis development and progression and to develop novel therapeutic strategies for the treatment of established UM liver metastases.

Role: Co-PI

**Past Grant Support**

Source: March of Dimes, Basil O’Connor Starter Grant

Title: Transcription Function of WT1

PI: Jonathan D. Licht, M.D.

Dates: 9/1/92-8/31/94 (non-renewable)

Source: Council for Tobacco Research

Title: Transcription Function of WT1

PI: Jonathan D. Licht, M.D.

Dates: 1993-1995 (Funding Agency no longer in operation)

Source: Leukemia Society of America

Title: The role of PLZF in Development

PI: Jonathan D. Licht, M.D.

Dates: 7/1/95-6/30/2000 (non-renewable)

Source: NIH 5U10CA21115 (Eastern Cooper Oncology Group)

Title: Gene Expression in Leukemia

PI: Robert Comis (ECOG Chairman’s Fund), Jonathan D. Licht, M.D.-Investigator

Dates 1/1/98-12/31/98

Costs: $40,000.

Source: American Cancer Society-DHP 160

Title: A genetic Approach to elucidate the role of the promyleocytic leukemia zinc finger (PLZF) gene in development

PI: Jonathan D. Licht, M.D.

Dates 7/1/95-6/30/02

Costs: $123,019/year Total $307,548

Source NIH/National Cancer Institute K08CA73762

Title: Transcriptional regulation by the PLZF Protein

PI: Ari M. Melnick, M.D. (Postdoctoral Fellow)

Mentor: Jonathan D. Licht, M.D.

Dates 7/1/97-6/30/02

Costs $79,020/yr, Total $400,000.

Source: Wellcome Trust

Title: The role of the sprouty gene in renal development

PI: Albert Basson, Ph.D.

Mentor: Jonathan D. Licht, M.D.

Dates: 2/1/01-1/31/03

Costs: $32,000/yr

Source: PKD Foundation

Title: The role of sprouty in polycystic kidney disease

PI: Jonathan D. Licht, M.D. 5% Effort

Dates 1/1/03-12/31/04

Costs $50,000/year total

Source: Multiple Myeloma Research Foundation

Title: The Function of the MMSET Protein in Myeloma

P.I.- Jonathan D. Licht, M.D.

Dates: 1/1/03-12/31/04

Costs: $100,000

Source NIH/NCI PO1 CA80058 Stuart Aaronson-PI

Title: p53-Regulators and Effectors

Dates: 1/1/94-12/31/04

Project 4 BRCA1 and p53 as regulators of transcription and cell growth

Costs: $146,535/yr

Source: Abbot Pharmaceuticals % effort-NA

Title: Valproic Acid for AML

PI: Andres Sirulnik, M.D.

Co-PI Jonathan D. Licht, M.D.

Dates: 9/1/02-8/31/04

Costs: $40,000

Source NIH/NCI R01 CA102270

Title: WT1 and ß-Catenin Targets in Wilms Tumor

Dates: 7/1/03-6/30/08

P.I: Benjamin Tycko, MD-PI (Columbia University)

 Jonathan D. Licht, M.D. (Co-PI)

Costs: $89,000

Source NIH/NIDDK P01DK062345

Title:" Sprouty In The Regulation Of Renal Development And PKD

Dates: 7/1/03-6/30/08

P.I. Patricia Wilson, PhD

 Jonathan D. Licht, M.D. –Project Leader 3

Costs: $ 129,901

Source: Burroughs-Wellcome Foundation

Title: Targeting aberrant transcription repression in leukemia

P.I. Jonathan D. Licht, M.D.

Dates: 7/1/02-6/31/08

Costs: $150,000/year

Source: Multiple Myeloma Research Foundation

Title: The Function of the MMSET Protein in Myeloma

P.I.- Jonathan D. Licht, M.D.

Dates: 9/1/05-8/31/07

Costs: $100,000

Source: NIH RO1 CA-59936

Title: The PLZF gene of t(11;17)-Promyelocytic Leukemia

Dates: 3/3/03-1/31/09

PI: Jonathan D. Licht

Costs: $253,800

Source: NIH RO1 CA-59998

Title: Sprouty, A WTI Target for Growth and Development

Dates: 01/18/07 – 12/31/10

PI: Jonathan D. Licht

Costs: $168,286

Source: NIH R01HL082950

Title: The Molecular Pathology of Myeloproliferative Disease

Dates: 09/06/06 – 08/31/11

PI: Jonathan D. Licht

Costs: $491,581

Source: NIH R01CA123204

Title: Transcriptional Functions and Targets of the MMSET Protein

Dates: 01/01/09 – 12/31/13

PI: Jonathan D. Licht

Costs: $200,000/yr

Source: 3P30CA060553 (Rosen)

Title: The Robert H. Lurie Comprehensive Cancer Center

Dates: 03/01/06– 7/31/12

PI: Jonathan D. Licht

Costs: 20% effort

Source: Multiple Myeloma Research Foundation

Title: Elucidation of MMSET Targets in Myeloma

Dates: 2/1/11-2/28/13

PI: Jonathan D. Licht

Costs: $125,000

|  |  |
| --- | --- |
| Source | MPN Foundation |
| Title: | Myelofibrosis Challenge Grant |
| Date: | 10/1/13-9/30/14 |
| Costs: | $100,000 |
| Source |  NIH/NCI U54 Physical Sciences Oncology Center (T. O’Halloran-PI) |
| Title: |  Coding, Decoding, Transfer, and Translation of Information in Cancer |
| Dates:Costs: |  07/01/15 – 07/31/14  Total: 131,366/yr (Project 2) |

|  |  |
| --- | --- |
| Source | Samuel Waxman Cancer Research Foundation |
| Title: | Mechanisms of EZH2 inhibitor resistance |
| Dates:Costs: | 07/01/11 – 06/30/15$45,000 |
| Source: | P30 CA060553 |
| Title: | Robert H. Lurie Comprehensive Cancer Center |
| Dates:Costs: | 08/01/13 – 09/30/15 (Left NU at that time)20% effort  |
| Source: | NIH/NCI P50 SPORE in Myeloma (K. Anderson-PI) |
| Title: | Project 4- Targeting the Multiple Myeloma Epigenome |
| Dates:Costs: | 09/01/13 – 08/31/18$100,000 (Project 4) |

|  |  |
| --- | --- |
| Source: | NIH/NCI U54 Physical Sciences of Oncology Center  |
| Title: | Spatio-Temporal organization of chromatin and information transfer in cancer |
| Dates:Costs: | 05/19/15 – 04/30/20 $150,000 (Project 2) |

|  |  |
| --- | --- |
| Source: | Leukemia and Lymphoma Society  |
| Title: | Consortium for The Study of Chromatin Biology In Hematological Malignancy |
| Dates:Costs: | 10/01/07 - 09/30/17$1,042,000 |

|  |  |
| --- | --- |
| Source: | Multiple Myeloma Research Foundation |
| Title: | Program Grant in Epigenetics |
| Dates: | 4/1/13-3/31/17 |
| Costs: | $500,000/yr |

|  |  |
| --- | --- |
| Source: | St. Baldricks Foundation  |
| Title: | The Role of MMSET in Relapsed Acute Lymphocytic Leukemia |
| Dates:  | 07/01/15 – 12/30/16 |
| Costs: | $100,000 |

Source: NIH F30CA203292

Title: Chromatin dysregulation generated by recurrent point mutation in histone methyltransferase, MMSET, drives progression of lymphoid malignancies

Dates: 6/20/16-6/21/17

PI: Alok Swaroop

Mentor: Jonathan D. Licht

Costs: $75,782

Source: NIH R01CA175349

Title: Molecular Targets of Translocation T(4:14) in Multiple Myeloma Pathogenesis

Dates: 1/1/16-12/31/18

PI: Michael Tomasson

Co-I: Jonathan D. Licht

Costs: $67,308

Source: Multiple Myeloma Research Foundation

Title: Chromatin Writers, Readers and Erasers in Multiple Myeloma

Dates: 10/1/15-11/30/19

PI: Jonathan D. Licht

Costs: $648,128

Source: NIH R01CA187109

Title: Targeting EZH2 in Germinal Center Derived B-Cell Lymphoma

Dates: 8/1/16-7/31/18

PI: Ari Melnick

Co-I: Jonathan D. Licht

Costs: $176,690

Source: NIH R01CA180475

Title: UTX, MLL, and Pathogenic Deregulation of Histone Methylation in Multiple Myeloma

Dates: 6/1/16-2/28/21

PI: Jonathan D. Licht

Costs: $987,427

Source: Florida Biomedical Research Program 7BC05

Title: Defining and targeting epigenetic deregulation in uveal melanoma

Dates: 4/12/17-2/29/20

PI: Kieran Smalley

Co-PI: Jonathan D. Licht

Costs: $382,088

Source: Florida Biomedical Research Program 8BC03

Title: Defining and therapeutically targeting HDAC8-driven reprogramming in melanoma brain metastasis development

Dates: 4/2/18-3/31/21

PI: Kieran Smalley

Co-PI: Jonathan D. Licht

Costs: $161,551

Source: Florida Biomedical Research Program 8LA01

Title: Identification of Therapeutic Targets and Pathways In Relapsed Childhood Acute Lymphocytic Leukemia Associated With NSD2 Mutation

Dates: 5/11/18-4/30/21

PI: Jonathan D. Licht

Costs: $173,913

**PUBLICATIONS (ORCID ID 0000-0002-3942-1369)**

**Google Scholar**

**H index: 86 (29,467 citations), Since 2017: H Index 48 (9169 citations)**

***Original Reports***

1. Hong RA, Licht JD, Wei JY, Heller GV, Blaustein AS, Pasternak RC. Elevated CKMB with normal total creatine kinase in suspected myocardial infarction: Associated clinical findings and early prognosis. Am Heart J 111:1041-1047, 1986.

2. Licht JD, Garnick MB: Phase II trial of strepozocin in the treatment of advanced renal cell carcinoma. Cancer Treat Rep 71:97-98, 1987.

3. Licht JD, Grossel MA, Figge J, Hansen UM. *Drosophila* *Krüppel* Protein is a Transcriptional Repressor. Nature 346:76-79, 1990.

4. Licht JD, Bosserman LD, Andersen JW, Yeap BY, Klatt MM, Martel JK, Anderson KC, Rosenthal DS, Pinkus G, Skarin AT, Canellos GP. Treatment of low and intermediate grade lymphoma with intensive chemotherapy leads to long term disease-free survival.

 Cancer 66:632-639, 1990.

5. Seiden MV, O'Donnell WJ, Weinblatt M, Licht JD. Vasculitis and recurrent pulmonary hemorrhage in a long term survivor after autologous transplantation for lymphoma. Bone Marrow Transplantation 6:345-347, 1990.

6. Licht JD, Gonin R, Antman KH. Phase II trial of trimetrexate in patients with advanced soft tissue sarcoma. Cancer Chemother Pharmacol 28:223-225, 1991.

7. DeFranco C, Ro M, Grossel M, Hansen UM, Wagner JA, Licht JD. NGF1A (EGR1) contains transcription activating domains in both the amino and carboxyl terminal regions of the protein. Biochem Bipohys Res Comm 194: 425-431, 1993.

8. Licht JD, Ro M, English MA, Grossel M, Hansen U. Selective repression of transcriptional activators at a distance by the *Drosophila* *Krüppel* protein.

 Proc Natl Acad Sci USA, 90: 11361-11365, 1993.

9. Licht JD, Hanna-Rose W, Reddy JC, English MA, Ro M, Grossel M, Shaknovich R,

 Hansen U. Mapping and mutagenesis of the amino terminal repression domain of the *Drosophila* Krüppel protein. Mol Cell Biol 14: 4057-4066, 1994.

10. Licht JD, Mazanet R, Loehrer, PJ, Gonin R, Antman K. Phase 4 trial of daily oral etoposide in the treatment of advanced soft tissue sarcoma. Cancer Chemother Pharmacol 34: 79-80, 1994.

11. Scott A, Head, DR, Kopecky KJ, Appelbaum FR, Theil KS, Grever MR, Chen I-M,

 Whitaker MH, Griffith BB, Licht JD, Waxman S, Whalen MM, Bankhurst AD, Richter LC, Grogan TM, Willman CL. HLA-Dr-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: A previously unrecognized form of acute leukemia potentially misdiagnosed as French- American British acute myeloid leukemia-M3. Blood 84:244-255, 1994.

12. Chen A, Licht JD, Wu Y, Hellinger N, Scher W and Waxman S. Retinoic acid is required for and potentiates superinduction of differentiation of acute promyelocytic leukemia cells by non- retinoid inducers. Blood 84: 2122-2129, 1994.

13. Licht JD, Chomienne C, Goy A, Chen A, Wu Y, Scott AA, Miller WH Jr., Zelenetz AD, Willman CL, Head DR, Chen Z, Chen S-J, Zelent A, Macintyre E, Veil A, Cortes J,

 Kantarjian H, Waxman S. Clinical and molecular characterization of a rare syndrome of acute promyleocytic leukemia associated with t(11;17) and fusion of the PLZF and RAR genes.

 Blood 85: 1083-1094. 1995.

14. Cook M, Gould A, Brand N, Davies J, Reid A, Strutt P, Shaknovich R, Licht J, Waxman S, Chen Z, Krumlauf R, Zelent A. Evolutionarily conserved expression of the leukemia translocation gene PLZF during neurogenesis and hemopoiesis.

 Proc Natl Acad Sci USA 92:2249, 1995.

15. Reddy JC, Morris J, Wang J, English MA, Haber DA, Shi Y, Licht JD. WT1-mediated transcriptional activation is inhibited by dominant-negative mutant proteins.

 J Biol Chem 270: 10878-10884, 1995.

16. Luo XN, Reddy JC, Levy PL, Haber DA, Licht JD, Atweh GH. The WT1 tumor suppressor gene inhibits *ras* mediated growth and transformation. Oncogene 11: 743-750, 1995.

17. Reddy JC, Hosono S, Licht JD. The transcriptional effect of WT1 is modulated by choice of expression vector. J Biol Chem 270: 29976-29982, 1995.

18. Reid A, Gould A, Brand N, Cook M, Strutt P, Li J, Licht J, Waxman S, Krumlauf R, Zelent A. Leukemia translocation gene PLZF is expressed with a speckled nuclear pattern in early hematopoietic progenitor cells. Blood 86: 4544-4552, 1995.

19. Licht JD, Shaknovich R, Melnick A, English MA, Li J-Y, Reddy JC, Dong S, Chen S-J, Zelent A, Waxman S. Reducedand Altered DNA-Binding And Transcriptional Properties Of The PLZF-Retinoic Acid Receptor- Chimera Generated In t(11;17)-Associated Acute Promyelocytic Leukemia. Oncogene 12:323-336, 1996

20. Duong S, Zhu J, Reid A, Strutt P, Guidez F, Zhong H-J, Wang Z-Y, Licht J, Waxman S, Chomienne C, Chen Z, Zelent A, Chen S-J. Amino-terminal protein-protein interaction motf (POZ domain) is responsible for the activites of promyelocytic leukemia associated PLZF-RAR fusion protein. Proc Natl Acad Sci USA 93:3624-3629, 1996.

21. Johnstone RW, See RH, Sells SF, Wang J, Muthukkumar S, Englert C, Haber DA, Licht JD, Sugrue SP, Roberts T, Rangnekar VM, Shi Y. A novel repressor par-4 modulates transcription and growth suppression functions of the Wilms' tumor suppressor, WT1.

 Molecular and Cellular Biology, 16:6945-6956, 1996.

22. Holmes G, Botahvelili S, English MA, Wainwright BJ, Licht JD, Little MH. Two N-terminal self-association domains are required for the dominant negative transcriptional activity of WT1 Denys-Drash Mutant Proteins. Biochem Bipohys Res Comm, 233: 723-728, 1997.

23. Hanna-Rose W, Licht JD, Hansen U. Two evolutionarily conserved repression domains in the *Drosophila Krüppel* protein differ in activator specificity. Mol Cell Biol 17: 4820-4829, 1997.

24. Li JY, English, MA, Ball H, Yeyati PL, Waxman S, Licht JD. Sequence-specific DNA binding and transcriptional regulation by the Promyelocytic Leukemia Zinc Finger Protein. J Biol Chem 272: 22447-22455, 1997.

25. Somasundaram K, Zhang H, Zeng Y-X, Houvras Y, Wu GS, Peng Y, Zhang H, Licht JD,

 El-Deiry WS, Weber BL. BRCA1 inhibition of the cell cycle requires p21WAF1/CIP1.

 Nature 389: 187-190, 1997.

26. Koken MHM, Reid A, Quiquon F, Chebi-Alix MK, Davies JM, Kabarowski JHS, Zhu J, Dong S, Chen S-J, Chen Z, Tan CC, Licht JD, Waxman S, de Thé H, Zelent A. Leukemia-associated RAR fusion partners PML and PLZF heterodimerize and colocalize onto nuclear bodies. Proc Natl Acad Sci USA 94: 10255-10260, 1997.

27. Carroquino MJ, Galson SK, Licht J, Amler RW, Perera FP, Claxton LD, Landrigan PJ. The U.S. EPA Conference on Preventable Causes of Cancer in Children: A Research Agenda.

 Environ Health Perspect 106(Suppl 3):867-873, 1998

28. Shaknovich RS, Yeyati PL, Ivins S, Melnick A, Lempert C, Waxman S, Zelent A, Licht JD. The Promyelocytic Leukemia Zinc Finger Protein Affects Myeloid Cell Growth, Differentiation and Apoptosis. Mol Cell Biol 18: 5533–5545, 1998.

29. Hosono S, Luo XL, Wilson PD, Burrow CR, Reddy, JC, Hyink DP, Schnapp LM, Atweh GH, Licht JD. WT1 expression induces features of renal differentiation in mesenchymal fibroblasts. Oncogene, 18: 417-427, 1999.

30. Hummel JL, Wells RA, Dubé ID, Licht JD, Kamel-Reid S. Deregulation of NPM and PLZF in a variant t(5;17) case of acute promyelocytic leukemia. Oncogene, 18: 633-642, 1999.

31. Yeyati PL, Shaknovich R, Ball HJ, Boterashvili S, Li J-Y, Waxman S, Zelent A, Licht JD.

 Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A.

 Oncogene 18:925-934, 1999.

32. Koken MHM, Daniel MT, Giannì M, Zelent A, Licht J, Degos L, Varet B, de Thé H. Retinoic Acid, but not Arsenic trioxide, degrades the PLZF/RAR fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17) APL patient.

 Oncogene 18: 1113-1118, 1999.

33. English, MA., Licht JD. Tumor-associated WT1 missense mutants indicate that transcriptional activation is essential for growth control. J Biol Chem 274: 13258-13263, 1999.

34. van Schothorst EM, Prins DEM, Baysal BE, Beekman M, Licht JD, Waxman S, Zelent A, Cornelisse CJ, van Ommen GJB, Richard III CW, Devilee P. Genomic structure of the human PLZF gene. Gene 236 21–24, 1999.

35. Ball H, Melnick A, Shaknovich R, Kohanski R, Licht JD. PLZF binds DNA as a high molecular weight complex in association with cell cycle regulatory proteins.

 Nucleic Acids Research 27: 4106-4113, 1999.

36. Zhang T, Xiong H, Kan L-X, Zhang C-K, Jia, X-F, Fu, G, Tong J-H, Gu B-W, Yu M, Licht J, Waxman S, Zellent A, Chen E, Chen S-J. Genomic sequence, structural organization, molecular evolution and aberrant rearrangement of the promyelocytic leukemia zinc finger gene. Proc Natl Acad Sci U S A. 96: 11422-11427, 1999

37. Melnick A; Fruchtman S; Zelent A; Liu M, Huang Q; Calasanz# MJ, Fernandez A, Licht JD,

 Najfeld V. Novel chromosomal rearrangements involving genetic loci usually associated with acute promyelocytic leukemia. Leukemia 13:1534-38, 1999.

38. Hoatlin ME, Zhi Y, Ball H, Silvey K, Melnick A, Stone S, Arai S, Hawe N, Owen G, Zelent A, Licht, JD. A novel BTB/POZ Transcriptional Repressor Protein Interacts With The Fanconi Anemia Group C Protein And PLZF- Blood. 94:3737-3747, 1999.

39. Melnick A, Westendorf J, Pollinger A, Arai S, Ball H Hiebert SW, Licht JD. Functional and physical interaction between the PLZF and ETO proteins. Mol Cell Biol 20: 2075-2086, 2000.

40. Hosono S, Gross I, English MA, Hadja K, Fearon E, Licht JD. E-Cadherin is a WT1 target Gene.

 J Biol Chem 275:10943-10953, 2000.

41. Melnick A, Ahmad KF, Arai S, Polinger A, Ball H, Borden KL, Carlile GW, Privé GG, Licht JD. In Depth Mutational Analysis of the PLZF BTB/POZ Domain Reveals Motifs and Residues Required for Biological and Transcriptional Functions. Molecular and Cellular Biology, 20: 6550–6567, 2000.

42. Melnick A, Carlile GW, McConnell MJ, Polinger A, Hiebert SW, Licht JD. The AML-1/ETO Fusion Protein is a Dominant Negative Inhibitor of Transcriptional Repression by PLZF. Blood. 96: 3939-47, 2000.

43. Houvras Y, Benezra, M., Zhang H, Manfredi JJ, Weber BL, Licht JD. BRCA1 Physically and Functionally Interacts with ATF1. J Biol Chem 275:36230-36237, 2000.

44. Srivastava DK, Tendler CL, Milani D, English MA, Licht JD, Wilson SH. The HIV-1 transactivator protein Tat is a potent inducer of the DNA repair enzyme ß-polymerase. AIDS 15:433-440, 2001

45. The acute promyelocytic leukemia associated protein, PLZF, inhibits 1,25(OH)2D3-induced monocytic differentiation of U937 cells through a physical interaction with VDR. WardJ, McConnell M, Carlile GW, Pandolfi PP, Licht JD, and Freedman LP. Blood, 98: 3290-3300, 2001.

46. Zhao F, Satoda M, Licht JD, Owa C, Gelb BD. Cloning and characterization of a novel mouse AP-2 transcription factor AP2, with unique DNA binding and transactivation properties. J Biol Chem 276:40755-40760, 2001.

47. Gross I, Bassit B, Benezra M, Licht, JD. Mammalian Sprouty Proteins Inhibit Cell Growth And Differentiation By Preventing Ras Activation- J Biol Chem 276: 46460–46468, 2001.

48. MelnickA, Carlile G, Ahmad KA, Kiang K Bardwell V, Prive GG, Licht JD. Critical Residues Within the BTB Domain of PLZF and Bcl6 Modulate Interaction with Co-Repressors. Mol and Cellular Biology 22:1804-1818, 2002.

49. Dai M-S, ChevallierN, StoneS, Heinrich MC, McConnellMJ, ReuterT, BroxmeyerHE, LichtJD, Li LuL, Hoatlin ME. The effects of the Fanconi anemia zinc finger (FAZF) on cell cycle, apoptosis and proliferation are differentiation-stage specific. J Biol Chem 277:26327-3, 2002.

50. Takahashi S, Licht JD. The human promyelocytic leukemia zinc finger gene is regulated by the Evi-1 oncoprotein and a novel guanine-rich site binding protein . Leukemia 16:1755-62, 2002.

51. McLoughlin P, Ehler E, Carlile G, Licht JD, Schäfer BW. The p53-inducible protein DRAL/FHL2 functionally interacts with the Promyelocytic Leukemia Zinc Finger protein.

 J Biol Chem. 277:37045-53, 2002

52. Labbaye C, Quaranta M, Pagliuca A, Militi S, Licht J, Testa U, Peschle C. PLZF induces megakaryocytic development, activates Tpo receptor expression and interacts with GATA 1 protein

 Oncogene 21:6669-79, 2002

53. Schumacher V, Schuhen S, Sonner S, Weirich A, Leuschner I, Harm D, Licht J, Roberts S, Royer-Pokera

 B. Two molecular subgroups of Wilms tumors with or without *WT1* mutations. Clinical Cancer Research

 9:2005-14, 2003.

54. Benezra M, Chevallier N, Morrison DJ, MacLachlan TK, Wafik S. El-Deiry WS, Licht JD. BRCA1

 augments transcription by the NF- B transcription factor by binding to the Rel domain of the p65/RelA

 subunit. J Biol Chem 278:26333-2641, 2003.

55. Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A, Hahlen K, Hasle H, Licht JD, Gelb BD. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet. 34:148-50, 2003

1. GrossI, MorrisonD, Hyink DP, GeorgasK, Milton A. EnglishMA, Hosono S, WilsonPD, Little M,

 Licht JD. The Receptor Tyrosine Kinase Inhibitor Sprouty1 Is A Target Gene of The Tumor

 Suppressor WT1 During Kidney Development. J. Biol. Chem. 278:41420-4143, 2003.

57. McConnell MJ, Chevallier N, Berkofsky-Fessler W, Giltnane J, Malani RB, Staudt LM, Licht JD. Growth Suppression by Acute Promyelocytic Leukemia-Associated Protein PLZF is Mediated by Repression of c-Myc Expression- Mol Cell Biol 24:9375-88, 2003.

58. Ahmad KF, Melnick A, Lax S, Bouchard D, Li J, Kiang C-L, Mayer S, Takahashi S, Licht JD, Privé GG. Mechanism of SMRT Corepressor Recruitment by the BCL6 BTB Domain.

 Molecular Cell 6:1551-64, 2003

59. Chevallier N, Corcoran C Lennon C, Bardwell V, Licht JD, Melnick A. ETO is a Co-Repressor for Bcl-6 in Both Normal and Malignant B-Lymphocytes. Blood 103:1454-63, 2004.

60. Mason JM, Morrison DJ, Bassit B, Dimri M, Band H, Licht JD, Gross I. Tyrosine phosphorylation of sprouty proteins stimulates their ability to inhibit growth factor signaling- a negative feed back loop. Molecular Biology of the Cell 15:2176-88, 2004.

1. Takahashi S, Harigae H, KakuM, SasakiT, Licht JD. Flt3 Mutation Activates p21WAF1/CIP1

Gene Expression Through the Action of STAT5- Biochem Biophys Res Commun 316:85-92, 2004.

1. Takahashi S, McConnell MJ, HarigaeH, Mitsuo KakuM Takeshi, Sasaki T, Melnick AM

 Licht JD.The Flt3 Internal Tandem Duplication Mutant Inhibits the Function of Transcriptional

 Repressors by Blocking Interactions with SMRT. Blood 103:4650-8, 2004.

63. Tsavachidou D, Coleman ML, Athanasiadis G, Li S, Licht JD, Olson MF, Weber BL. BRAF mutations bypass SPRY-dependent negative feedback inhibition of MAPK pathway signaling. Cancer Research 64:5556-9, 2004.

64. Guo, G, Morrison DJ, Licht JD, Quaggin SE. WT1 Activates a Glomerular-Specific Enhancer Identified from the Human Nephrin Gene,. J Amer Soc Nephrol, 15 :2851-6, 2004.

65. Polo JM, Dell’Oso T, Ranuncolo SM, Cerchietti L, Beck D, Da Silva GF, Prive GG, Licht JD, Melnick AA. Specific Peptide Interference Reveals Bcl-6 Transcriptional Mechanisms and Oncogenic Role in B-Cell Lymphoma. Nature Medicine, 10:1329-35, 2004.

66. Li C-M, Kim CE, Margolin AA, Guo M, Zhu J, Mason JM, Hensle TW, Murty VVVS, Grundy PE, Fearon E, D’Agati V, Licht JD, Tycko B. CTNNB1 mutations and over-expression of Wnt/beta-catenin target genes in WT1-mutant Wilms tumors. Amer J Path 6:1943-1953, 2004.

# 67. Olsson M, Mason JM, English MA, Licht JD, Ekblom P. WT1 binding sites in the promoter region of human and mouse nucleoporin 210, a marker for epithelial cells. J Negat Results Biomed. 3:7, 2004.

# 68. Basson MA, Akbulut S, Watson-Johnson J, Simon R, Carroll TJ, Shakya R, Gross I, Martin GR, Lufkin T, McMahon AP, Wilson PD, Costantini FD, Mason IJ, Licht JD. Sprouty1Is A Critical Regulator Of GDNF/Ret-Mediated Kidney Induction-Developmental Cell 8:229-239, 2005.

69. Lin W, Jing N, Basson A, Licht J, Ang S-L. Synergistic activity of Sef and Sprouty proteins in regulating the expression of *Gbx2* in the mid-hindbrain region- Genesis 41:110-115, 2005.

70. Guidez F, , Howell, L Isalan M, Cebrat M, Alani RM, Ivins, S, HormaecheI, McConnell MJ, Pierce S, Cole PA, Licht J, Zelent A. Histone acetyltransferase activity of p300 is required for transcriptional repression by the Promyelocytic Leukemia Zinc Finger protein. Mol Cell Biol, 25:5552-66, 2005.

71. Takahashi S, Harigae H, Ishii KI, Inomata M, Fujiwara T, Yokoyama H, Ishizawa K, Kameoka J,

 Licht JD, Sasaki T, Kaku M. Over-expression of Flt3 induces NFB pathway and increases the

 expression of IL-6. Leukemia Research 29: 893-899, 2005.

72. Morrison DJ, English ME, Licht JD. WT1 induces apoptosis through transcriptional regulation of the pro-apoptotic Bcl-2 family member Bak. Cancer Research 65:8174-82, 2005.

73. BassonMA, Watson-Johnson J, ShakyaR, Hyink D, Akbulut S, Costantini FD, Wilson PD, Mason IJ, Licht JD. Branching morphogenesis of the ureteric epithelium during kidney development is coordinated by the opposing functions of GDNF and Sprouty1- Dev Biol 299:466-47, 2006

74. [Bowler T, Kosman D, Licht JD, Pick L.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16996052&query_hl=1&itool=pubmed_docsum) Computational identification of Ftz/Ftz-F1 downstream target genes. Dev Biol 299:78-90, 2006.

75. Denne M, Sauter M, Armbruester V, Licht JD, Roemer K, Mueller-Lantzsch N. Physical and functional interactions of human endogenous retrovirus proteins Np9 and rec with the promyelocytic leukemia zinc finger protein. J Virol. 81:5607-5616, 2007.

76. Gaiddon C, Armant O, Benosman S, Gonzales de Aguilar J-L, Freund JN, Kedinger M, Loeffler J-P, Licht JD and Gross I Sprouty2 inhibits BDNF-induced signaling and modulates neuronal differentiation and survival. Cell Death and Differentiation 14:1802-12, 2007

77. Maekawa T, Sano Y, Shinagawa T, Rahman Z, Sakuma T, Nomura S, Licht JD, Ishii S. ATF-2 controls transcription of Maspin and GADD45alpha genes independently from p53 to suppress mammary tumors. Oncogene. 27:1045-54, 2008

78. Kim MKH, Mason JM, Li C-M, Berkofsky-Fessler W, Choubey D, Grundy PE, Tycko B, Licht JD. A Pathologic Link between Wilms Tumor Suppressor Gene, WT1, and IFI16. Neoplasia 10:69-78, 2008.

79. MarangoJ, ShimoyamaM, NishioH, MeyerJA, MinD-J, Sirulnik, Martinez- Martinez Y, ChesiM, BergsagelPL, ZhouM-M, WaxmanS, LeibovitchBA, WalshMJ, Licht JD. The MMSET Protein is a Histone Methyltransferase with Characteristics of a Transcriptional Co-repressor. Blood, 111:3145-54, 2008.

80. Petrie K, Guidez F, Zhu J, Owen G, Chew YP, Waxman S, Licht J, Mitternach S, Zelent A. Retinoblastoma protein interacts with and enhances activity of the leukemia associated PLZF transcriptional repressor. Oncogene, 27:5260-6, 2008.

81. Morrison DJ, Kim MKH, Berkofsky-Fessler W, Licht JD. WT1 Induction of MKP3 Represents a Novel Mechanism of Growth Suppression. Molecular Cancer Research 7:1225-31, 2008

82. Polo JM, Ci W, Licht JD, Melnick A. Reversible disruption of BCL6 repression complexes by CD40 signaling in normal and malignant B-cells. Blood, 112:644-51, 2008

83. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, Castoldi M, Soutschek J, Koteliansky V, Rosenwald A, Basson MA, Licht JD, Pena JT, Rouhanifard SH, Muckenthaler MU, Tuschl T, Martin GR, Bauersachs J, Engelhardt S. [MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signaling in fibroblasts.](http://www.ncbi.nlm.nih.gov/pubmed/19043405?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum) Nature 456:980-4, 2008.

84. Wen Q, Leung C, Huang Z, Small S, Lakku Reddi A, Licht JD, Crispino JD. [Survivin is not required for the endomitotic cell cycle of megakaryocytes.](http://www.ncbi.nlm.nih.gov/pubmed/19339696?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum) Blood 114:153-6, 2009.

85. Xu D, Holko M, Sadler AJ, Scott B, Higashiyama S, Berkofsky-Fessler W, McConnell MJ, Pandolfi PP, Licht JD, Williams BRG. Promyelocytic Leukemia Zinc Finger Protein Regulates Interferon-Mediated Innate Immunity. Immunity 30:802-16, 2009.

86. Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi SH, Yang AS, Aucott T, Dauses T, Odchimar-Reissig R, Licht J, McConnell MJ, Nasrallah C, Kim MK, Zhang W, Sun Y, Murgo A, Espinoza-Delgado I, Oteiza K, Owoeye I, Silverman LR, Gore SD, Carraway HE. Reversal of Promoter Methylation is Not Required for Clinical Response in Patients with Myeloid Malignancies Receiving Therapy With Combination 5-azacitidine and Entinostat. Blood 114:2764-73, 2009

87. Kim MKH, McGarry TJ, Broin PO, Flatow JM, Golden AA-J, Licht JD. An Integrated Genome Screen Identifies The WNT Signaling Pathway As A Major Target Of WT1. Proc Natl Acad Sci USA 106:11154-9, 2009.

88. Figueroa ME, Skrabanek L, Li Y, Jiemjit A, Fandy T,Paietta E, Tallman MS, Greally JM Carraway H Licht JD, Gore SD, Melnick AM. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 114:3448-58, 2009.

89. Chi X, Odyssé Michos O, Shakya R, Licht JD, Mendelsohn CL, Costantini F, Ret-dependent cell rearrangements in the Wolffian duct epithelium initiate ureteric bud morphogenesis. Dev Cell, 17:199-209, 2009

90. Doulatov S, Notta F, Rice KL, Howell L, Janmohamed S, Iscove N, ZelentA LichtJD, Dick JE. Identification of PLZF as a critical switch between human steady-state and cytokine-induced myelopoiesis- Genes Dev 23:2076-87, 2009.

91. RiceKL, Hormaeche, Doulatov, Flatow J, Grimwade D, Mills KI, Dick JE, Licht JD. Comprehensive Genomic Screens Identify a Role for PLZF-RAR as a Positive Regulator of Cell Proliferation via Direct Regulation of c-MYC. Blood 114:5499-511, 2009

92. Michos O, Hyink D, Grieshammer U, D’Agati V, LichtJD, MartinGR, Costantini F. Latent redundancy between Gdnf and Fgf10 during kidney development is revealed by loss of Sprouty1- I PLOS Genetics. Jan 15;6(1):e1000809, 2010

93. Shea KL, Wanyi Xiang W, LaPorta VS, Licht JD, Keller C, Basson MA, Andrew S. Brack AS. Sprouty1 regulates self-renewal of the adult muscle stem cell pool during regeneration. Cell Stem Cell 6 :117-129, 2010

94. Gilbert PM, Mouw JK, Unger MA, Lawkins JN, Gbegnon MK, Clemmer VB, Benezra M, Licht JD, Boudreau NJ, Tsai KKC, Welm AL, Feldman MD, Weber BL, Weaver V. HoxA9 regulates BRCA1 expression to modulate mammary tissue growth and survival- J Clin Invest. 120:1535-50, 2010.

95. Berkofsky-Fessler W, Buzzai M, Kim MKH, Fruchtman S, Najfeld V, Min DJ, Costa FF, Bischof JM, Soares MB, McConnell MJ, Zhang W, Levine R, Gilliland DG, Calogero R, Licht JD. Transcriptional Profiling Of Polycythemia Vera Identifies Gene Expression Patterns Both Dependent And Independent From The Action Of JAK2V617F. Clinical Cancer Res 16: 4339-52, 2010

96. AkbulutS, Reddi AL, Ambardekar C, Canciani C, Kim MKH, Laura Hix L, Vilimas T, Mason J, Basson MA, Lovatt M, Powell J, Collins S, Quatela S, Phillips M, Licht JD. Sprouty Proteins Inhibit Receptor-Mediated Activation Of Phosphatidylinositol-Specific Phospholipase C. Mol Biol Cell, 21:3487-3496, 2010.

97. Kim, MKH, Min DJ, Rabin M, Licht JD. Characterization of Functional roles of Wilms Tumor SuppressorWTX and tumor associated WTX mutants. Oncogene 30:832-42, 2010

98. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Löwenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A. Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. Cancer Cell 8:553-67, 2010

99. Lagha M, Sato T, Regnault B, Cumano AD, Zuniga A, Licht J, Relaix F, Buckingham M. Transcriptome analyses based on genetic screens for Pax3 myogenic targets in the mouse embryo. BMC Genomics. 11:696, 2010.

100. Martinez-Garcia E, Popovic R, Min DJ, Sweet SMM, Thomas PM, Zamborg L, Heffner A, Will C, Lamy L, Staudt LM, Levens DL, Kelleher NL, Licht JD. The MMSET Histone Methyl Transferase Switches Global Histone Methylation and Alters Gene Expression in t(4;14) Multiple Myeloma Cells. Blood 117:211-20, 2011

101. Kuracha PR, Burgess D, Siefker E, Cooper J, Licht JD, Robinson, ML, Govindarajan V. Spry1 and Spry2 are necessary for lens and corneal differentiation. Investigative Ophthalmology & Visual Science. 52:6887-97, 2011

102. Rice KL, Lin, X, Ebert BL, Berkofsky-Fessler W, Buzzai M, Sun Y, Xi C, Elkin P, Levine RL, Golub T, Gilliland DG, Licht JD, Zhang W. Integrative analysis of genomic aberration and gene expression revealed a novel role of Jak2 V167F in gene expression regulations in Myeloproliferative Disorder. Blood Cancer J. 2011 Nov;1(11):e40. doi: 10.1038/bcj.2011.39.

103. Tefferi A, Abdel-Wahab O, Cervantes F, Crispino JD, Finazzi G, Girodon F, Gisslinger H, Gotlib J, Kiladjian J-J, Levine RL, Licht JD, Mullally A, Odenike T, Pardanani A, Silver RT, Solary E, Mughal T. Mutations with putative epigenetic effect in myeloproliferative neoplasms and recent progress in prognostication and treatment: proceedings from the 5th international post-ASH symposium. Blood Cancer J. 2011 Mar 4;1:e7. doi: 10.1038/bcj.2011.4.

104. Biyashev D, Veliceasa D, Mizgirev I , Redd AL, Licht JD, Revskoy SY, Volpert OV. miRNA-27b promotes tip cell fate, sprouting and arterial-venous segregation by blocking Notch and Sprouty pathways. Blood. 119:2679-87, 2012

105. Sathyanarayana P, DevA, PradeepA, LichtJD, Wojchowski DM. Spry1 Acts As A Non-Redundant Regulator Of Erythropoiesis, Prime EpoR Target, And Novel Jak2 Suppressor- Blood. 119:5522-31, 2012

106. Hwangpo TA, Jordan D, Premsiriut P, Jayamaran G, Licht JD, Iyengar R, Neves SR. GRIN modulates Sprouty2 inhibitory effects on MAPK activation by growth factor stimulation- J Biol Chem. 287:13674-85, 2012.

107. Kentsis A, Reed C, Rice KL, Sanda T, Rodig SJ, Tholouli E, Valk P, Delwel R, Ngo V, Kutok JL, Dahlberg SE, Moreau LA, Byers RJ, Christensen JG, Vandewoude G, Licht JD, Kung AL, Staudt LM, Look AT. Aberrant expression of hepatocyte growth factor induces autocrine activation of MET, providing a novel therapeutic target in acute myeloid leukemia- Nat Med. 18:1118-22, 2012

108. Zheng Y, Sweet SMM, Tipton JD, Popovic R, Martinez-Garcia E, Thomas PM, Licht JD, Kelleher NL. A Bidirectional Antagonism between Histone H3 Lysine 27 and 36 Determines Their Combinatorial Methylation Patterns *in vivo*. Proc Natl Acad Sci U S A. 109:13549-54, 2012.

109. Collins SL, Waikman A, Basson MA, Licht JD, Horton MR, Powell JD. Regulation of CD4+ and CD8+ Effector responses by Sprouty-1. PLoS One. 2012;7(11):e49801

110. Sharma B, Josh S, Sassano A, Majchrzak B, Kaur S, Aggarwal P, Nabet B, Bulic M, Stein BL, McMahon B, Baker DP, Fukunaga R, Altman JK, Licht JD, Fish N, Platanias LC. Sprouty proteins are negative regulators of interferon (IFN)-signaling and IFN-inducible biological responses. J Biol Chem. 287: 42352-60, 2012

111. Min DJ, Ezponda T, Kim, MKH, Will CM, Martinez-Garcia E, PopoviaR, Basrur V, Elentoba-Johnson K, Licht JD. MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC- Leukemia 27:686-94, 2013

112. Sena LA, Li S, Jairaman A, Prakriya M, Ezponda T, Hildeman DA, Wang C-R, Schumacker PT, Licht JD, Perlman H, Bryce PJ, Chandel NS. Mitochondria are required for antigen-specific T cell activation through ROS signaling. Immunity. 38:225-36, 2013.

113. Lin X, Rice KL, Buzzai M, Hexner E, Costa FF, Kilpivaara O, Mullally A, Soares MB, Ebert BL, Levine R, Licht JD. miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation. Leukemia 27:344-52, 2013

114. Petruccelli LA, Pettersson F, del Rincon SV, Guilbert C, Licht JD, Miller Jr. WH. Expression of leukemia associated fusion proteins increases sensitivity to histone deacetylase inhibitor induced DNA damage and apoptosis. Mol Cancer Ther 12:1591-60, 2013

115. Ezponda T, Popovic R, Shah MY, Martinez-Garcia E, Zheng Y, Min DJ, Will CM, Neri A, Yu J, Kelleher NL, Licht JD. The Histone Methyl Transferase MMSET Activates *TWIST1* to Promote an Epithelial-Mesenchymal Transition and Invasive Properties of Prostate Cancer- Oncogene 32:2882-90, 2013

116. Béguelin W, Popovic R, Teater M, Jiang Y, Bunting K, Garcia M, Shen H, Yang SN; Wang L, Ezponda T, Martinez-Garcia E, ; Zhang H, Zhang Y, Verma S, McCabe M, Ott H, Van Aller G, Kruger R, Liu Y, McHugh C, Scott D, Chung YR, Kelleher N, Shaknovich R, Creasy C, Gascoyne R, Wong K-K, Cerchietti L, Levine R, Abdel-Wahab O, Licht JD\*, Elemento O\*, Melnick A\*. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23:677-92, 2013. \*Co-Corresponding Author

117. Sullivan LB, Garcia-Martinez E, Nguyen H, Mullen AR, Dufour E, Sudarshan S, Licht JD, Deberardinis RJ, Chandel NS. The Proto-oncometabolite Fumarate Binds Glutathione to Amplify ROS-Dependent Signaling. Mol Cell. 51:236-48, 2013.

118. Physical Sciences - Oncology Centers Network, Agus DB, Alexander JF, Arap W, Ashili S, Aslan JE, Austin RH, Backman V, Bethel KJ, Bonneau R, Chen WC, Chen-Tanyolac C, Choi NC, Curley SA, Dallas M, Damania D, Davies PC, Decuzzi P, Dickinson L, Estevez-Salmeron L, Estrella V, Ferrari M, Fischbach C, Foo J, Fraley SI, Frantz C, Fuhrmann A, Gascard P, Gatenby RA, Geng Y, Gerecht S, Gillies RJ, Godin B, Grady WM, Greenfield A, Hemphill C, Hempstead BL, Hielscher A, Hillis WD, Holland EC, Ibrahim-Hashim A, Jacks T, Johnson RH, Joo A, Katz JE, Kelbauskas L, Kesselman C, King MR, Konstantopoulos K, Kraning-Rush CM, Kuhn P, Kung K, Kwee B, Lakins JN, Lambert G, Liao D, Licht JD, Liphardt JT, Liu L, Lloyd MC, Lyubimova A, Mallick P, Marko J, McCarty OJ, Meldrum DR, Michor F, Mumenthaler SM, Nandakumar V, O'Halloran TV, Oh S, Pasqualini R, Paszek MJ, Philips KG, Poultney CS, Rana K, Reinhart-King CA, Ros R, Semenza GL, Senechal P, Shuler ML, Srinivasan S, Staunton JR, Stypula Y, Subramanian H, Tlsty TD, Tormoen GW, Tseng Y, van Oudenaarden A, Verbridge SS, Wan JC, Weaver VM, Widom J, Will C, Wirtz D, Wojtkowiak J, Wu PH. A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep. 2013 Apr 25;3:1449.

119. Oyer JA, Huang X, Zhen Y, Shim J, Ezponda T, Allegretta M, Okot-Kotbr CI, Patel JP, Melnick A, Levine RL, Ferrando A, MacKerell Jr AD, Kelleher NL, Licht JD, Popovic R. Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies- Leukemia. 2014 Jan;28:198-201, 2014

120. Mehrotra S, Sharma B, Joshi S, Kroczynska B, Majchrzak B, Stein BL, McMahon B, Altman JK, Licht JD, Baker DP, Eklund EA, Wickrema A, Verma A, Fish EN, Platanias LC. Essential role for the Mnk-pathway in the inhibitory effects of Type I interferons on myeloproliferative neoplasm (MPN) precursors. J Biol Chem. 288:23814-22, 2013.

1. Kuracha MR, Siefker E, Licht JD, Govindarajan V. Spry1 and Spry2 are necessary for eyelid closure. Dev Biol. 383:227-38, 2013.
2. Small EC, Xi L, Wang JP, Widom J, Licht JD. Single Cell Nucleosome Mapping Reveals the Molecular Basis of Gene Expression Heterogeneity. Proc Natl Acad Sci, USA. 111:E2462-71, 2014.
3. Choi WI, Yoon JH, Kim MY, Koh DI, Licht JD, Kim K, Hur MW. Promyelocytic Leukemia Zinc Finger-Retinoic Acid Receptor α (PLZF-RARα), an Oncogenic Transcriptional Repressor of Cyclin-dependent Kinase Inhibitor 1A (p21WAF/CDKN1A) and Tumor Protein p53 (TP53) Genes. J Biol Chem. 289:18641-18656, 2014.
4. Popovic R, Martinez-Garcia E, Giannopoulou E, Zhang Q, Ezponda T, Shah MY, Zheng Y, Will CM, SmallEC, Hua Y, Bulic M, Jiang Y, Carrara M, Calogero RA, Kath W, Kelleher NL, Wang JP, Elemento E, Licht JD. Histone Methyltransferase MMSET Alters EZH2 Binding and Reprograms the Myeloma Epigenome Through Global and Focal Changes in H3K36 and H3K27 Methylation. PLoS Genet. 10(9):e1004566. doi: 10.1371/journal.pgen.1004566. 2014
5. Saloura V, Cho H-S, Kyiotani K, Alachkar H Zuo Z, Nakakido M, Tsunoda T, Seiwert T, Lingen M Licht J, Nakamura Y, Hamamoto RW. Wolf-Hirschhorn Syndrome Candidate 1 Promotes Oncogenesis through Regulation of NIMA-related-kinase-7 in Squamous Cell Carcinoma of the Head and Neck. Mol Cancer Res; 13:293-304, 2015.
6. Rampal R, Alkalin A, Madzo J Vasanthakumar A, Pronier E, , Patel J, Li Y, Ahn J, Abdel-Wahab O, Shih A, Lu C, Ward PS, Tsai JJ, Hricik T, Li Y, Tosello V, Tallman JE, Zhao X, Daniels D, Dai Q, Ciminio L, Pollyea D, Aifantis I, He C, Fuks F, Tallman MS, Ferrando A, Nimer S, Paietta E, Thompson CB, Licht JD, Mason C, Godley LA, Melnick A, Figueroa ME, Levine RL. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Rep. 2014 Dec 3. pii: S2211-1247(14)00958-9.
7. Zhou Z, Gao J, Popovic R, Wolniak K, Parimi V, Winter JN, Licht JD, Chen Y-H. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma (DLBCL) independent of EZH2 Y641 mutation and cell of origin. Leuk Lymphoma. 56:2895-901, 2015
8. Nabet B, Ó Broin P, Shieh K, Lin CY Will CM, Popovic R, Ezponda T, JBradner JA, Golden AA, Licht JD. Deregulation of the Ras-Erk signaling Axis Modulates the Enhancer Landscape. Cell Reports. pii: S2211-1247(15)00822-0. <http://dx.doi.org/10.1016/j.celrep.2015.06.078>
9. Zheng Y, Fornelli L, Compton PD, Sharma S, Canterbury J, Mullen C, Zabrouskov V, Fellers RT, Thomas PM, Licht JD, Senko MW, Kelleher NL. Unabridged Analysis of Human Histone H3 by Differential Top-Down Mass Spectrometry Reveals Hypermethylated Proteoforms from MMSET/NSD2 Overexpression. Mol Cell Proteomics 15:776-90, 2016.
10. McConnell MJ, Durand L, Langley E, Coste-Sarguet L, Zelent A, Chomienne C, Kouzarides T, Licht JD, Guidez F. Post transcriptional control of the epigenetic stem cell regulator PLZF by sirtuin and HDAC deacetylases. Epigenetics Chromatin. 2015 Sep 24;8:38. doi: 10.1186/s13072-015-0030-8. eCollection 2015.
11. Shah MY, Martinez-Garcia E, Popovic R, Phillip JM, Chambliss AB, Phillip MP, Ezponda T, Small EC, Will C, Neri P, Bahlis NJ, Wirtz D, Licht JD. MMSET/WHSC1 enhances DNA damage repair and increases resistance to chemotherapeutic agents. Oncogene. 35:5905-5915, 2016. PMID 27109101.
12. Dupéré-Richer D, Kinal M, Pettersson F, Emond A, Calvo-Vidal MN, Nichol JN, Guilbert C, Plourde D, Klein Oros K, Nielsen TH, Ezponda T, Licht JD, Johnson NA, Assouline S, Cerchietti L, Miller WH Jr, Mann KK. Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors. Leuk Lymphoma 58: :218-221, 2017
13. Arcipowski, KM, Bulic M, Gurbuxani S, Licht, JD. Loss of Mll3 catalytic function promotes aberrant myelopoiesis. PLoS One. 2016 Sep 9;11(9):e0162515. doi: 10.1371/journal.pone.0162515.
14. Schauwecker SM, Kim JJ, Licht JD, Clevenger CV. Histone H1 and Chromosomal Protein HMGN2 Regulate Prolactin-Induced STAT5 Transcription Factor Recruitment and Function in Breast Cancer Cell. J Biol Chem. 2016 Dec 29. pii: jbc.M116.764233. doi: 10.1074/jbc.M116.764233
15. Mahajan N, Wu H-J, Bennett RL, Troche C, Licht JD, Weber JD, Maggi LB Jr, Tomasson MH. Sabotaging of the oxidative stress response by an oncogenic non-coding RNA. FASEB J. 31:482-490, 2017.
16. Ezponda T, Varghese N, Patel T, SmallEC, WillC, Nabet B, Popovic R, Oyer J, Bulic M, Zheng Y, Huang X, Shah M, Kelleher N, Keats J, Occhionorelli M, Tonon G, Licht JD. UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition. Cell Rep 21:628-640, 2017.
17. Yang X, Gong Y, He Q, Licht JD, Liaw L, Friesel RE. Loss of Spry1 attenuates vascular smooth muscle proliferation by impairing mitogen-mediated changes in cell cycle regulatory circuits. J Cell Biochem. 119:3267-3279, 2018.
18. Tocco VJ, Li Y, Christopher KG, Matthews JH, Aggarwal V, Paschall L, Luesch H, Licht JD, Dickinson RB, Lele TP. The nucleus is irreversibly shaped by motion of cell boundaries in cancer and non-cancer cells. J Cell Physiol. 2018 233:1446-1454, 2018.
19. Fantini D, Glaser AP, Rimar K, Wang Y, Schipma M, Varghese N, Rademaker A, Behdad A, Yellapa A, Yu Y, Crawford SE, Hu D, Licht JD, Collings C, Bartom E, Theodorescu D, Shilatifard A, Meeks JJ. A Carcinogen-induced Mouse Model Recapitulates the Molecular Alterations of Human Muscle Invasive Bladder Cancer. Oncogene. 37:1911-1925, 2018
20. Melo-Cardenas J, Xu Y, Wei J, Tan C, Kong S, Gao B, Montauti E, Kirsammer G, Licht JD, Yu J, Ji P, Crispino JD, Fang D. USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1 dependent mechanism. Blood. 2018 May 29. pii: blood-2017-10-811760. doi: 10.1182/blood-2017-10-811760.
21. Luo H, Wang F, Li H, Du Q, Yan B, Chen S, Sobh A, Vulpe C, Drusbosky L, Cogle C, Chepelev I, Xu B, Nimer S, Licht J, Chen B, Qiu Y Xu M, Huang S. Targeting CTCF boundary remodels chromatin domain and reprograms *HOX* gene transcription in acute myeloid leukemia. [Blood.](https://www.ncbi.nlm.nih.gov/pubmed/?term=Targeting+CTCF+boundary+remodels+chromatin+domain+and+reprograms+HOX+gene+transcription+in+acute+myeloid+leukemia) 2018 May 14. pii: blood-2017-11-814319. doi: 10.1182/blood-2017-11-814319. [Epub ahead of print]
22. Kim J, Lee Y, Lu X, Song B, Fong KW, Cao Q, Licht JD, Zhao JC, Yu J. Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator. Cell Rep. 2018 Dec 4;25(10):2808-2820.e4. doi: 10.1016/j.celrep.2018.11.035.
23. Swaroop A, Oyer JA, Will CM, Huang X, Yu W, Troche C, Bulic M, Durham BH, Wen QJ, Crispino JD, MacKerell AD Jr, Bennett RL, Kelleher NL, Licht JD An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia. Oncogene 38:671-686, 2019
24. Alakoski T, Ulvila J, Yrjölä R, Vainio L, Magga J, Szabo Z, Licht JD, Kerkelä R. Inhibition of cardiomyocyte Sprouty1 protects from cardiac ischemia-reperfusion injury. Basic Res Cardiol. 114:7, 2019
25. Emmons MF, Faião-Flores F, Sharma R, Thapa R, Messina JL, Becker JC, Schadendorf D, Seto E, Sondak VK, Koomen JM, Chen YA, Lau EK, Wan L, Licht JD, Smalley KSM. HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy. Cancer Res 79:2947-2961, 2019.
26. Vaquero M, Anerillas C, Cuesta-Sancho S, Egea J, Ribera J, Licht JD, Basson, MA Encinas M. Sprouty1 Controls Genitourinary Development via its N-Terminal Tyrosine. J Am Soc Nephrol.  30:1398-1411, 2019.
27. Faião-Flores F, Emmons M, Durante M, Kinose F, Saha B, Fang B, Koomen J, Chellappan S, Maria-Engler S, Rix U, Licht JD, Harbour JW, Smalley K. HDAC inhibition enhances the in vivo efficacy of MEK inhibitor therapy in uveal melanoma. Clin Cancer Res 18:5686-570, 2019.
28. Huang X, LeDuc RD, Fornelli L, Schunter AJ, Bennetr RL, Kelleher NL, Licht JD. Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding-  J Biol Chem. 294:12459-12471, 2019
29. Bennett RL, Bele A, Eliza C. Small EC, Will CM, Nabet B, Oyer JA, Ghosh RP, Grzybowski AT, Yu T Zhang Q, Riva A, Lele TP, Schatz GC, Ruthenburg AJ, Liphardt J, Licht JD. A Mutation in Histone H2B Represents a New Class of Oncogenic Driver. Cancer Discovery 10:1438-1451, 2019.
30. Jiang Y, Gao R, Forbes L, Li J, Freeberg S, Fredenburg KM, Cao C, Justice J, Wu L, Licht JD, Zajac-Kaye M, Kentsis A, Kaye F. MYB-activated models for testing therapeutic agents for adenoid cystic carcinoma. Oral Oncol. Oral Oncol. 98:147-155, 2019
31. Avezedo JG, Faião-Flores F, Emmons MF, Aplin AE, Harbour JW, Licht JD, Wink MR , Smalley KSM. Decitabine limits escape from MEK inhibition in uveal melanoma [published online ahead of print, 2019 Nov 23]. Pigment Cell Melanoma Res. 2019;10.1111/pcmr.12849. doi:10.1111/pcmr.12849
32. Cheong CM, MroziK KM, Hewett DR, Panagopoulos V, Noll JE, Licht JD, Gronthos S, Vandyke K, Zannettino AC. MMSET/NSD2-regulated Twist-1 promotes tumour migration and dissemination in multiple myeloma. Cancer Lett. 475:99-108, 2020.
33. Tamashunas AC, Tocco VJ, Matthews J, Zhang Q, Li G, Paschall L, Pathak S, Stephens AD, Luesch H, Licht JD, Lele TP. High-throughput gene screen reveals modulators of nuclear shape. Mol Biol Cell. 2020 Apr 22:mbcE19090520. doi.
34. Sheng Y, Yu C, Liu Y, Hu C, Ma R, Lu X, Ji P, Chen J, Mizukawa B, Huang Y, Licht JD, Qian Z. FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML. Nat Commun. 2020 Feb 17;11(1):928. doi: 10.1038/s41467-020-14590-9.
35. Ordoñez R, Kulis M, Russiñol N, Chapaprieta V, Beekman R, Meydan C, Duran-Ferrer M, Verdaguer-Dot N, Clot G, Vilarrasa-Blasi R, Garate L, Miranda E, Carrasco-Leon A, Ezponda T, Dupéré-Richer D, Martens J, Torrents D, El Omri H, Y Taha R, Calasanz M, Paiva B, San Miguel J, Flicek P, Gut I, Melnick A, Mitsiades C, Licht J, Campo E, Stunnenberg H, Agirre X, Prosper F, Jose Martin-Subero J. Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma. Genome Res. 30:1217-1227, 2020.
36. Yusufova N, Soshnev AA, Kloetgen A, Teater M1, Osunsade A, Doane A, Camarello J, Philips J, Conway J, Bott M, Elemento O, Beguelin W, LichtJD, Kelleher N, Staudt LM, Skoultchi A, Apostolou E, Imilienski M, David Y, Tsirigos A, Allis CD, Cesarman C, Melnick A. Histone 1 deficiency drives lymphomagenesis through disruption of 3D chromatin architecture.Nature 589:299-305, 2021
37. Longo J, Smirnov P, Li Z, Branchard E, van Leeuwen JE, Licht JD, Haibe-Kains B, Andrews DW, Keats JJ,Pugh TJ,Trudel S,Linda Z. Penn LZ. The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma- Leukemia 35:796-808, 2021
38. Shirasaki R, Matthews GM, Gandolfi S, de Matos Simoes R, Buckley DL, Raja J, Sievers QL, Brüggenthies JB, Dashevsky O, Poarch H, Tang H, Bariteau MA, Sheffer M, Hu Y, Downey-Kopyscinski SL, Hengeveld PJ, Glassner BJ, Dhimolea E, Ott CJ, Zhang T, Kwiatkowski NP, Laubach JP, Schlossman RL, Richardson PG, Culhane A, Groen RWJ, Fischer ES, Vazquez F, Tsherniak A, Hahn WC, Levy J, Auclair D, Licht JD, Keats J, Boise LH, Ebert BL, Bradner JE, Gray NS, Mitsiades CS. Functional genomics identify distinct and overlapping genes mediating resistance to different classes of heterobifunctional degraders of oncoproteins. Cell Rep 34:108532, 2021
39. Joos K, Schachner LF, Watson R, Gillespie ZB, Howard SA, Cheek MA, Keogh M-C, Licht JD, Kelleher NL. Separation and Characterization of Endogenous Nucleosomes by Native Capillary Zone Electrophoresis – Top-Down Mass Spectrometry. Analytical Chemistry 93:5151-5160, 2021.
40. Hogg SJ, Motorna O, Johanson TM, Coughlan HD, Todorovski I, Pijpers L, Dupéré-RicherD, Kearney C, Breon Feran, Knight D, Cluse LA, Martin BP, Khong T, Spencer A, Harrison SJ, Gregory G, Smyth GK, Allan RS, Papenfuss AT, Bromberg KD, Lai A, Licht JD, Shortt J, Vervoort SJ, Ricky W. Johnstone RW. Histone acetylation dynamics control transcription independently from chromatin structure. Molecular Cell 81:2183-2200, 2021.
41. Zee BM, oels, KE Yao C-H, Kawabata, KC , Wu G, Duy C, Jacobus WD, Senior E, JEndress JE, Jambhekar A, Lovitch SB, Ma J, DhallA, Harris IS, Blanco MA, Sykes DB, Licht JD, Weinstock DM, Melnick A, Haigis, MC, Michor F, Shi Y. Combined Epigenetic and Metabolic Treatments Overcome Differentiation Blockade in AML-iScience, 2021 https://doi.org/10.1016/j.isci.2021.102651
42. Guo Y, Szurek SM, Bian J, Braithwaite D, Licht JD, Shenkman E. The role of sex and rurality in cancer fatalistic beliefs and cancer screening utilization in Florida. Cancer Med. 2021 Jul 13. doi: 10.1002/cam4.4122. Online ahead of print.
43. Li J, Hlavka-Zhang J, Shrimp JH, Piper C, Dupéré-Richér D, Roth JS, Jing D, Román HC, Troche C, Swaroop A, Kulis M, Oyer J, Will C, Shen M, Riva A, Bennett RL, Ferrando AA, Hall MD, Lock RB, Licht JD. A Gain of Function Mutation of The NSD2 Histone Methyltransferase Drives Glucocorticoid Resistance in Pediatric Acute Lymphoblastic Leukemia. Cancer Discovery 12: 186–203, 2022.
44. VenugopalK, Nowialis P, Feng Y, Shabashvili DE, Berntsen CM, Krajcik KI, Taragjini C, Zaroogian Z, Casellas Román HL, Posada LM, Gunaratne C, Li J, Dupéré-Richer D, Bennett RL, Pondugula S, Riva AL, Cogle CR, Law BK, Kubicek S, Staber PB, Licht JD, Opavsky R, Bird JE, Guryanova OA. DNMT3A with leukemia-associated mutations directs sensitivity to DNA damage at replication forks. Clin Cancer Res. 2021 Oct 29. doi: 10.1158/1078-0432.CCR-21-2863.
45. Li L, Sheng P, Li T, Fields CJ, Hiers NM, Wang Y, Li J, Guardia CM, Licht JD, Xie M. Widespread microRNA degradation elements in target mRNAs can assist the encoded protein. Genes & Development 35:1595-1609, 2021
46. Preston SEJ, Emond A, Pettersson F, Dupere-Richer D, Malakhveitchouk A, Dobocan MC, Kinal M, Oros KK, del Rincón A, Licht JD, Miller Jr WH. Acquired resistance to EZH2 inhibitor GSK343 promotes the differentiation of DLBCL cell lines towards an ABC-like phenotype. Mol Cancer Ther 21:511-521, 2022.
47. Sriramareddy SN, Faião-Flores F, Emmons MF, Saha B, Chellappan S, Wyatt C, Smalley I, Licht JD, Durante MA, Harbour JW, Smalley KSM. HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma. Cancer Gene Ther 2022 Mar 24. doi: 10.1038/s41417-022-00452-7.
48. Zhang D, Leeuwenburgh C, Zhou D, Gong Y, Pahor M, Licht JD, Braithwaite, D. Analysis of Biological Aging and Risks of All-Cause and Cardiovascular Disease–Specific Death in Cancer Survivors. JAMA Netw Open. 2022;5(6):e2218183. doi:10.1001/jamanet
49. Kellish PC, Dib PE, Barrigon MV, Paciaroni NG, Nawab A, Andring J, Kulemina L, Borrero NV, Modenuti C, Bennett R, Shabashvili D, Licht JD, McKenna R, Roitberg R, R Huigens III RW, Kaye FJ, Zajac-Kaye M. Targeting thymidylate synthase inhibition by multifunctional non-classical antifolates inhibits tumor progression and extends survival. Submitted
50. Pei J, Xiao Y, Liu X, Wanyi Hu W, Sobh A, Yuan Y, Zhou S, Hua N, G Mackintosh SG, Zhang X, Basso KB, Kamat M, Yang Q, Licht JD, Zheng G, Zhou D, Lyu D. Identification of Piperlongumine (PL) as an E3 ligase ligand to induce targeted protein degradation. Submitted Angewandte Chemie
51. Finkle, JD, Nabet B, Licht JD, Bagjeri N. Gene regulation dynamics reveal Sprouty mediated regulation of angionegnic factors Submitted-PloS Computaional Biology.
52. Hall H, Szurek S, Cho HD, Guo Y, Gutter M, Licht JD, Shenkman EA. Investigating below the county level to reveal poverty-related cancer disparity. Submitted.
53. de Matos Simoes R, Shirashaki R, Downey-Kopyscinski SL, Matthews GM, Barwick, BG, Gupta VA, Dupéré-Richér D, Yamano S, Hu Y, Sheffer M, Dhimolea E, Dashevsky O, Gandolfi S, Meyers RM, Bryan JG, Dharia NV, Hengeveld PJ, Br√ºggenthie JB, Tang H, Aguirre AJ, Sievers QL Ebert BL, Glassner BJ, Ott CJ, Bradner JE, Kwiatkowski NP, Auclair D, Levy J, Keats JJ, Groen RWJ, Gray NS, Culhane AC, McFarland JM, Dempster JM, Licht JD, Boise LH, Hahn WC, Vazquez F, Tsherniak A, Mitsiades CS. Genome-scale functional genomics studies identify genes preferentially essential for myeloma cells vs. other neoplasias. In preparation, 2022.
54. Hanley RP, Nie DY, Tabor JR, Li F, Sobh A, Xu C , Barker NK, Dilworth D, Hajian T, Gibson E, Szewczyk MM, Brown PJ, Barsyte-Lovejoy D, Herring LE, Wang GG, Licht JD, Vedadi M, Arrowsmith CH, James LI. Discovery of a potent and selective targeted NSD2 degrader for reduction of H3K36me2. Submitted. Cell Chemical Biology, 2022.
55. Kaler CJ, Dollar JJ, Cruz AM, Kuznetsoff JN, Sanchez1 MI, Decatur CL, Licht JD, Smalley KSM, Correa ZM, Kurtenbach S, Harbour JW. BAP1 loss promotes suppressive tumor immune microenvi-ronment via up-regulation of PROS1 in class 2 uveal melanomas. Submitted Cancers

***Invited Reviews***

1. Licht JD, Weissman LB, Antman K. Gastrointestinal sarcomas. Sem Oncol 15: 181-188, 1988.

2. Reddy JC, Licht JD. The WT1 Wilms’ Tumor Suppressor Gene: How Much Do We Really Know? BBA Reviews in Cancer 1287(1): 1-28, 1996.

3. Tenen DG, Hromas R, Licht JD, Zhang D-E. Transcription factors, normal myeloid development and Leukemia. Blood 90: 489-519, 1997.

4. Melnick A, Licht JD. Deconstructing a Disease: RAR, its fusion partners and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93: 3167-3215, 1999.

5. Licht JD AML1 and The AML1-ETO Fusion Protein In The Pathogenesis Of t(8;21) AML. Oncogene 20: 5560-5679, 2001.

6. Licht JD. Targeting Aberrant Transcriptional Repression: A Therapeutic reality?

 J Clinical Investigation, 108: 1277-1278, 2001.

7. Zelent A, Guidez F, Melnick A, Waxman S, Licht JD. Translocations Of The *RAR* Gene In Acute Promyelocytic Leukemia. Oncogene 20: 7186- 7203, 2001.

1. Melnick A, Licht JD. Histone Deacetylases as Therapeutic Targets in Hematological Malignancies.

 Current Opinion in Hematology 9: 322-332, 2002.

9. Gross I, Licht JD. Sprouty Proteins, A New Family of Receptor Tyrosine Kinase Inhibitors

 Current Genomics 3: 285-293, 2002.

10. Johnstone RW, Licht JD Histone Deacetylase Inhibitors In Cancer Therapy-Is the Transcription the target? Cancer Cell 2003 4:13-8, 2003.

11. Sirulnik A, Melnick A, Zelent A, Licht JD. Molecular pathogenesis of acute promyelocytic leukaemia and APL variants. Best Pract Res Clin Haematol. 2003 16:387-408, 2003.

12. Sternberg DW, Licht JD. Therapeutic Intervention in Leukemias that Express the Activated FLT3 Tyrosine Kinase: Opportunities and Challenges- Current Opinion in Hematology, 12:7-13, 2005.

13. Licht JD, Zelent A. Retinoid and growth factor receptor signaling in APL. Blood 105:1381-2, 2005.

14. Melnick A, Adelson K, Licht JD. The Theoretical Basis of Transcriptional Therapy of Cancer:

 Can it be put into practice? J Clin Oncol 23: 3957-3970, 2005.

15. Sternberg DW, Licht JD. The Molecular Pathology of Acute Myeloid Leukemia. Hematology (Am Soc Hematol Educ Program). 2005:137-142, 2005.

16. Mason JM, Morrison, DJ, Basson MA, Licht JD. Sprouty Proteins: Multifaceted Negative Feedback Regulators Of Receptor Tyrosine Kinase Signaling. Trends Cell Biology 16: 45-54, 2006.

17. Licht JD. Reconstructing A Disease: What Essential Features Of The Retinoic Acid Receptor Fusion Oncoproteins Generate Acute Promyelocytic Leukemia? Cancer Cell 9: 73-74, 2006.

18. Licht JD. What Unleashes What Unleashes Aberrant Gene Regulation in APL? Blood 109:857, 2007.

19. Rice KL, Licht JD. HOX Gene Deregulation- A Common Theme in Acute Myelogenous Leukemia

 J Clin Invest. 117:865-868, 2007.

20. Hormache I, Licht JD. Chromatin Modulation by Oncogenic Transcription Factors-New Complexity, New Therapeutic Targets. Cancer Cell 6: 475-478, 2007.

21. Rice, KL, Hormache I, Licht JD. Epigenetic Regulation of Normal and Malignant Hematopoiesis.

 Oncogene 26: 6697-6714, 2007.

22. Frankfurt, O, Licht JD, Tallman MS. Molecular Characterization of Acute Myeloid Leukemia and its Impact in Treatment. Current Opinion in Oncology 19: 635-49, 2007.

23. Buzzai M, Licht JD. New Molecular Concepts and Targets in Acute Myeloid Leukemia- Current Opinion in Hematology, 15:82-87, 2008.

24. Licht JD. Acute Promyelocytic Leukemia and Weapons of Mass Differentiation. New Eng J Medicine 360:928-930, 2009.

25. Martinez-Garcia E, Licht JD. Deregulation of H3K27 Methylation in Cancer.

 Nat Genetics 42:100-101, 2010.

26. Min D-J, Licht JD. Partners In Crime: Genes Within An Amplicon Collude To Globally Deregulaton Chromatin in Lymphoma. Cancer Cell 18:539-41, 2010.

27. Popovic R, Licht JD. MM Flavors: Maf and MEK and Myeloma Therapy. Blood 117:2300-2302, 2011.

1. Shah MY, Licht JD. DNMT3A Mutations in AML. Nature Genetics, 29:289-90, 2011.
2. Shah MY, Licht JD. Epigenetics: What the Hematologist Should Know. The Hematologist, Spring 2011
3. Pettersson F, Miller WH Jr, Nervi C, Gronemeyer HJ, Licht J, Tallman MS, Waxman S. The 12th international conference on differentiation therapy: targeting the aberrant growth, differentiation and cell death programs of cancer cells. Cell Death Differ 18:1231-3, 2011
4. Popovic R, Licht JD. Emerging Epigenetic Therapies for Cancer, Cancer Discovery, 2: 405-13. 2012.
5. Khan I, Altman JK, Licht JD. New Strategies In Acute Myeloid Leukemia: Redefining Prognostic Markers To Guide Novel Therapies- Clin Cancer Res. 19: 5163-71, 2012
6. Beck S, Bernstein BE, Campbell RM, Costello JF, Dhanak D, Ecker JR, Greally JM, Issa JP, Laird PW, Polyak K, Tycko B, Jones PA; AACR Cancer Epigenome Task Force. A blueprint for an international cancer epigenome consortium. A report from the AACR Cancer Epigenome Task Force. Cancer Res. 2012 Dec 15;72(24):6319-24
7. Popovic R, Shah MY, Licht JD Epigenetic therapy of hematological malignancies: where are we now? Ther Adv Hematol 4:81-91, 2013.
8. Frankfurt O, Licht JD. Ponatinib - a step forward in overcoming resistance in chronic myeloid leukemia. Clin Cancer Res. 19:5828-34, 2013.
9. Licht JD, Shortt J, Johnstone R. From Anecdote to Targeted Therapy: The Curious Case of Thalidomide in Multiple Myeloma. Cancer Cell 25:9-11, 2014
10. Ezponda T, Licht JD. Different Paths, Same Destination: Deregulation of Histone 3 Lysine 27 Methylation In Cancer. Clin Cancer Res. 20:5001-8, 2014
11. Licht JD. DNA Methylation Inhibitors For Cancer Therapy-The Immunity Dimension. Cell 162:938-939, 2015.
12. Guryanova O, Licht JD. DNA  FQI1: a transcription-methylation switch for cancer. Oncotarget 8:12536-12537, 2017.

40. Bennett RL, Swaroop A, Troche C, Licht JD. The role of the NSD family of histone lysine methyltransferases in cancer. Cold Spring Harb Perspect Med. 2017 Jun 1;7(6). pii: a026708.

41. Dupéré-Richer D, Licht JD. Epigenetic Regulatory Mutations and Epigenetic Therapy For Multiple Myeloma. Current Opinion in Hematology 24:336-344, 2017.

42. Licht JD. SETD2: A Complex Role in Blood Malignancy. Blood. 130:2576-2578, 2017

43. Bennett RL, Licht JD. Targeting Epigenetics in Cancer. Annu Rev Pharmacol Toxicol 58:187-207, 2018.

44. Alzrigat M, Jernberg-Wiklund H, Licht JD. Targeting EZH2 in multiple myeloma – multifaceted anti-tumor activity. Epigenomes 2018, *2*(3), 16; https://doi.org/10.3390/epigenomes2030016

45. Licht, JD. Oncogenesis by E2A-PBX1 in ALL: RUNX and More. Blood. 136: 3-4, 2020.

46. Licht, JD. Histone H3 G34 Tail Mutations in Cancer: Actions in *cis* and *trans* to Alter Chromatin and Gene Expression. Cancer Discovery, 10: 1794-1976, 2020.

48. Prado G, Kaestner C, Licht JD, Bennett RL. Targeting epigenetic mechanisms to overcome venetoclax resistance. BBA Molecular Cell Research. 1868:119047, 2021.

47. Bennett RL, Licht JD. Leveraging Epigenetics to Enhance the Efficacy of Immunotherapy. Clinical Epigenetics 13:115, 2021.

***Book Chapters***

1. Licht JD, Tsiftsoglou A. Mechanisms involved in the Differentiation of Leukemia. In: Proceedings of the Sixth Annual Conference on Differentiation therapy. Serono Symposium Publications, Rome. 1996.

2. Licht JD. Clinical and Molecular Characterization of t(11;17) APL and the role of the PLZF Gene. In: Proceedings of the Sixth Annual Conference on Differentiation therapy. Serono Symposium Publications, Rome. 1996.

3. Licht JD, Waxman S. The promyelocytic leukemia zinc finger gene. Encyclopedia of Molecular Medicine, John Wiley & Sons, 2002.

4. Privé GG, Melnick AM, Ahmad KF, Licht JD. The BTB Zinc Finger Proteins. In: Zinc Finger Proteins: from Atomic Contact to Cellular Function [Editor: Iuchi S, Kuldell](http://www.eurekah.com/search.php?searchterm=Iuchi,%20Shiro,%20Natalie%20Kuldell),N, Eds., Landes Bioscience, 2004.

5. McConnell MJ, Licht JD. The PLZF Protein. In- Acute Promyelocytic Leukemia. Pandolfi, PP Editor- Curr Top Microbiol Immunol. 313:31-48, 2007

6. Rice KL, Buzzai M, Altman J, Licht JD. The Molecular Basis of Acute Myeloid Leukemia. In: Molecular Oncology  Causes of Cancer and Targets for Treatment. Gelmann, EP, Sawyers CL, Rauscher II FJ, Eds. Cambridge Univ Press, 2014

7. Nichol JN, Dupéré-Richer D, Licht JD and Wilson H. Miller, Jr. WH. Chapter 3: H327 Methylation: A Focal Point of Epigenetic Deregulation in Cancer. In: Advances in Cancer Research, 2016;131:59-95. doi: 10.1016/bs.acr.2016.05.001. Epub 2016 Jun 17.

8. Bennett RL, Licht JD. Epigenetics. In: Offermanns S., Rosenthal W. (eds) Encyclopedia of Molecular Pharmacology. Springer, Cham. https://doi.org/10.1007/978-3-030-57401-7\_10061, 2021.

###### Book Editing

K. Ravid, J.D. Licht- Transcription factors: Normal and malignant development of blood cells.

John Wiley and Sons, 2001

### *Electronic Media*

Alliance for Cellular Signaling/Nature Signaling Gateway

Gross I, Mason JM, Licht JD. Spry1 Full Molecule Page Published online: 18 Apr 2006 |doi:10.1038/mp.a002507.01

Mason JM, Gross I, Licht JD. Spry4 Full Molecule Page, Published online: 18 Apr 2006 |doi:10.1038/mp.a002507.01

Mason JM, Licht JD. Spry3 Full Molecule Page, Published online: 25 Feb 2005 |doi:10.1038/mp.a002509.01

Atlas of Genetics and Cytogenetics in Oncology and Haematology

### Martinez-Garcia E, Licht JD. WHSC1 (Wolf-Hirschhorn syndrome candidate 1).

### Atlas Genet Cytogenet Oncol Haematol. November 2008,

### <http://AtlasGeneticsOncology.org/Genes/WHSC1ID42809ch4p16.html>

### Nahbet, B, Licht JD. SPRY1

### Atlas Genet Cytogenet Oncol Haematol. October, 2013.

http://atlasgeneticsoncology.org/Genes/SPRY1ID51064ch4q28.html

### *Patents*

Patent-US8703503-Methods and compositions for inhibition of BCL6 repression. April 5, 2011. Inventors: Ari M. Melnick, Jonathan D. Licht, Gilbert Prive, Khaja Farid Ahmad

Application-PCT/US2015/021905- Methods of treating cancer. Inventors: Caretha L. Creasy, Jonathan Licht, Michael McCabe, Relja Popovic.

### *Licenses*

PLZF Monoclonal Antibody

MMSET Monoclonal Antibody

Spry1 Monoclonal Antibody

**INVITED LECTURES**

**1993**

• CUNY Biomedical Science Department, New York, New York

• New York Society for the Study of Blood

**1994**

• New York Region Fly Meeting, Cold Spring Harbor, New York

• Hematology Grand Rounds, Mount Sinai School of Medicine

• Dana-Farber Cancer Institute, Harvard Medical School, Boston

• Department of Pathology, SUNY Stony Brook

• Institute of Cancer Research, London, UK

**1995**

• Department of Genetics, Memorial Sloan Kettering Cancer Center

• Nephrology Research Seminar, Mount Sinai School of Medicine

• Neoplastic Diseases Grand Rounds, Mount Sinai School of Medicine

• Center for Blood Research, Harvard Medical School, Boston, MA

• Sixth International Conference on Differentiation, Herzalia, Israel

• FASEB Conference on Hematological Malignancies, Saxon River, VT

• Biochemistry Department, City University of New York

• Department of Pharmacology, Cornell University Medical Center

• Department of Pathology, Columbia University, P & S

**1996**

• Hematology Grand Rounds, Cornell University Medical Center

• Hematology Grand Rounds, Yale University Medical Center

• Breast Cancer Research Forum, Mount Sinai Medical Center

• Rockefeller University Hospital, New York, NY

• Molecular Medicine Rounds, Mount Sinai School of Medicine

• Neoplastic Diseases Grand Rounds, Mount Sinai School of Medicine

• Hematology Grand Rounds, Downstate Medical Center

• Department of Oncology, Johns Hopkins University

• Myeloid Differentiation Workshop/ASH, Orlando, Florida

**1997**

• Surgical Research Conference, Mount Sinai School of Medicine

• Ontario Cancer Institute, Toronto, Canada

• Molecular Aspects of Myeloid Stem Cell Development-Annapolis, Maryland

• FASEB Conference on Hematological Malignancies, Saxon River, VT

• National Institute of Human Genome Research, Bethesda, MD

• Seventh International Conference on Differentiation, Versailles, France

• First International Meeting on BRCA1/BRCA2 Function, Cambridge, UK

• Eastern Cooperative Oncology Group Leukemia Core Meeting, Orlando, Fl

**1998**

• Department of Biochemistry, Boston University School of Medicine

• Moffit Cancer Center, University of Florida, Tampa

• Mini Medical School, Mount Sinai School of Medicine

• Department of Biochemistry, University of Wisconsin, Madison, WI

• Chemotherapy Foundation Symposium XVI, New York, NY

• Hematology Grand Rounds, Mount Sinai School of Medicine

• Department of Pathology, Yale University School of Medicine

**1999**

• Leukemia Research Group, University of Pennsylvania

• Pediatric Oncology Rounds, Children's Hospital of Philadelphia

• Division of Hematology/ Oncology- Vanderbilt University Medical Center

• FASEB Conference on Hematological Malignancies, Saxon River, VT

• Leukemia Society of America Annual Scientific Symposium

• Hematology/Oncology Grand Rounds- Dana-Farber Cancer Institute

• Cancer Center Conference- Albert Einstein College of Medicine

• NY Flow Cytometry Users Group Meeting, Cornell Medical College

2000

• Department of Cell Biology- Albert Einstein College of Medicine

• Cancer Center Grand Rounds- University of Michigan

• Division of Gastroenterology - University of Pennsylvania

• Workshop on Hematological Malignancies- Pathology B Study Section, Keystone, Colorado

• Department of Pharmacology-Dartmouth Medical School

• Beth Israel-Deaconess Medical Center, Harvard Medical School

• Hematology Division- New York University School of Medicine

• 13th International Symposium on the Treatment of Leukemia, Lymphoma and Cancer, New York, NY

• 29th Annual Meeting of the International Society for Experimental Hematology

• Chromatin workshop, National Institutes of Health

• Marie Curie Institute Conference on Transcription, London, UK

• Institute of Cancer Genetics, Columbia University College of Physicians and Surgeons., NY

• Division of Clinical Sciences, Molecular Oncology Rounds, National Cancer Institute

• Institut de Recherches Cliniques de Montreal, Quebec

**2001**

**•** Keystone Symposium on Hematological Malignancies, Keystone CO

• FASEB Conference on Hematological Malignancies, Aspen, CO

• Gordon Conference on Chemotherapy, New Hampshire

• Fondation de Treilles conference on 10 years of the Molecular Biology of Acute Promyelocytic Leukemia, Toutour, France

• Ontario Cancer Institute, Toronto, Canada

• Ninth International Conference on Differentiation Therapy, Rome, Italy

• NIH Workshop on BRCA1, Rockville, MD

• Institut Gustave Rousay, Paris, France

**2002**

• Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, Piscataway, NJ

• Ohio State University, Columbus, Ohio

• University of Michigan Cancer Center, Ann Arbor, MI

• Massachusetts General Hospital Cancer Center, Boston, MA

• University of Massachusetts Medical Center, Worcester, MA

• Pathology Grand Rounds, Cornell University Medical Center, New York, NY

• Institut de Recherches Cliniques de Montreal, Quebec

• American Society of Nephrology Meeting, Session on Cell Cycle Control, Philadelphia, PA

• Department of Oncology, The Queen's University of Belfast, Northern Ireland

• National Institute for Medical Research, Mill Hill, UK

• Kings College, London, UK

• Pre-ASH Workshop on Myeloid Biology

• American Society of Hematology Meeting, Scientific Subcommittee on Neoplasia, Philadelphia, PA

**2003**

• University of Texas, Southwestern Medical School, Dallas, TX

• Workshop on Hematological Malignancies, Hopital St. Louis, Paris, France

• Mount Sinai Hospital 150th Anniversary Academic Symposium

• Medical Grand Rounds, Mount Sinai School of Medicine

• Molecular Aspects of Myeloid Development, Annapolis, MD

• Albert Einstein College of Medicine, Bronx, NY

• Kalpysis, Inc. San Diego, CA

• Syrrx, Inc., San Diego CA

• The Scripps Research Institute, San Diego, CA

• Erasmus Workshop on Molecular Targets in Leukemia, Rotterdam, Netherlands

• UCSF Cancer Center, San Francisco, CA

• Cold Spring Harbor Meeting on Signal Transduction, Cold Spring Harbor, NY

• Rockefeller University, New York, NY

• Englewood Hospital, Englewood, New Jersey

• Hematology/Oncology Grand Rounds, Northwestern University, Chicago. IL

• Grand Rounds- Department of Leukemia, MD Anderson Cancer Center, Houston, TX

• American Association for Cancer Research, Washington, DC

• Lauri Strauss Memorial Lecture/Medical Grand Rounds, Memorial Sloan Kettering Cancer Center, NY

**2004**

• University of Chicago, Chicago, IL

• University of Illinois Medical School, Chicago, IL

• Ovarian Cancer Research Group, Huntsman Cancer Center, University of Utah, Salt Lake City, UT

• American Association for Cancer Research, Orlando, FL

• Melanoma Group, University of Pennsylvania

• Leukemia and Lymphoma Society Symposium, American Society of Hematology, San Diego, CA

• American Society of Hematology, San Diego, CA

• Hematology Division, Yale University, New Haven, CT

• Hematology/Oncology Division, New York Medical College, Valhalla, NY

• Maimonides Medical Center, Brooklyn, NY

• Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

• Needham & Company Biotech Investors Conference, New York, NY

• Renal Division, University of Pennsylvania, Philadelphia, PA

• Hematology/Oncology Grand Rounds, Massachusetts General Hospital, Boston, MA

• Hematology/ Grand Rounds-St. Lukes/Roosevelt Hospital, New York, NY

**2005**

• Workshop on Clinical Translation of Epigenetics in Cancer Therapeutics, Charlestown, SC

• University of New Mexico Cancer Center, Albuquerque, NM

• Medical Grand Rounds- NYU School of Medicine, New York, NY

• H. Lee Moffit Cancer Center, University of Florida, Tampa, FL

• Needham & Company Biotech Investors Conference, New York, NY

• Molecular Aspects of Myeloid Stem Cell Development-Annapolis, MD

• American Society of Nephrology, Philadelphia, PA

• 4th International Symposium on Acute Promyelocytic Leukemia, Rome, Italy

• Institute of Cancer Genetics, Columbia University, New York, NY

• Educational Session- Acute Myeloid Leukemia, American Society of Hematology, Atlanta, GA

• Pre-ASH Workshop on Myeloid Biology, Atlanta, GA

• Visiting Professor, McGill University Lady Davis Institute, Montreal, Canada

• Indiana University, Indianapolis, IN

• Scientific Advisory Board Meeting, Phylogica, Inc. Bunker Bay, Western Australia

• Telethon Institute for Child Health Research, Perth, Western Australia

**2006**

• Fox Chase Cancer Center, Philadelphia, PA

• Loyola University Medical School, Chicago, IL

• Department of Pharmacology, Cornell-Weil College of Medicine, New York, NY

• University of Virginia Cancer Center, Charlottesville, VA

• Cancer 2006, Dublin, Ireland

• American Association for Cancer Research Annual Meeting, Washington, D.C.

• Visiting Professor, McGill University Lady Davis Institute, Montreal, Canada

• Shanghai Institute of Hematology. Shanghai, China

**2007**

• Biannual Johns Hopkins Workshop on Epigenetic Changes in Cancer Therapeutics, Phoenix, AZ

• FASEB Meeting on Hematological Malignancies, Saxtons Woods, VT

• Vanderbilt University, Nashville, TN

• World Nephrology Conference, Rio de Janeiro, Brazil

• Section of Hematology/Oncology-University of Chicago, Chicago, IL

• Shanghai Institute of Hematology, Shanghai, China

• Peking University Medical College, Beijing, China

• Visiting Professor, McGill University Lady Davis Institute, Montreal, Canada

• Department of Pathology, University of Michigan, Ann Arbor, MI

• Glaxo Smith Kline, King of Prussia, PA

2008

• Department of Pharmacology, Dartmouth University

• American Association for Cancer Research Annual Meeting, San Diego, CA

• Mari Lowe Lecturer, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA

• Cancer Center, University of California San Diego, San Diego, CA

• Medical Grand Rounds, Memorial Sloan Kettering Cancer Center, NY

• Visiting Professor, McGill University Lady Davis Institute, Montreal, Canada

• Endocrinology Research Conference, Northwestern University, Chicago, IL

• Nephrology Research Conference, Northwestern University, Chicago, IL

• International Conference on WT1, Manchester, UK

• King College London, London, UK

2009

• FASEB Meeting on Hematological Malignancies, Saxtons Woods, VT

• International Conference On Differentiation Therapy, Chicago, IL

• Gastroenterology Research Conference, University of Illinois, Chicago

• University Of Miami, Division of Hematology/Oncology

• National Institutes Of Health, Bethesda, MD

• 5th International Symposium on Acute Promyelocytic Leukemia, Rome, Italy

• Epitron Brainstorming Session, Montenegro (Delivered via Skype)

• Nephrology Research Conference, Northwestern University

• Keynote Speaker, Midwestern Blood Club, Cincinnati, Ohio

• Epizyme, Inc. Cambridge, MA

• Haddon Lecturer, Institute of Cancer Research Surrey, UK

• National Institute of Medical Research, London, UK

• Kings College, London, UK

• Cambridge University, Cambridge, UK

• Visiting Professor, McGill University Lady Davis Institute, Montreal, Canada

• Leukemia Lab Committee, Eastern Cooperative Oncology Group

• Pre-ASH Workshop on Myeloid Biology, New Orleans, LA

2010

• Department of Pharmacology, University of Pennsylvania, Philadelphia, PA

• Division of Hematology/Oncology, Columbia University, New York, NY

• Blood Discussion Group, University of Pennsylvania, Philadelphia, PA

• Dana-Farber Cancer Institute, Boston, MA

• Wells Center, Indiana University

• University of Connecticut, Center for Molecular Medicine, Farmington, CT

• First Annual Physical Sciences in Oncology Centers Meeting, National Harbor, MD

• University of Southern California, Center for Applied Molecular Medicine, Los Angeles, CA

• City of Hope Medical Center, Duarte, CA

• University of California Los Angeles Cancer Center, Los Angeles, CA

• Visiting Professor, McGill University Lady Davis Institute, Montreal, Canada

• Visiting Professor, New York University School of Medicine, New York, NY

• 72nd Annual Meeting of the Japanese Society of Hematology, Yokohama, Japan

• Cancer Science Institute of Singapore, Singapore

• Cincinnati Children’s Hospital, Cincinnati, Ohio

• Glaxo Smith Kline, King of Prussia, PA

• UCSF Cancer Center, San Francisco, CA

• Meet the Professor, American Society of Hematology, Orlando, FL

• 5th International CML & MPN Workshop, Orlando, FL

• Medical Grand Rounds, Best Manuscripts of 2009, Northwestern University

2011

• Biannual Johns Hopkins Workshop on Epigenetic Changes in Cancer Therapeutics, San Diego, CA

• FASEB Meeting on Hematological Malignancies, Saxtons Woods, VT

• European Hematology Association, London, UK

• Acute Leukemia XIII, Munich, Germany

• XIIIth International Myeloma Workshop, Paris, France

• Vth International Workshop on Myeloma Pharmacogenomics & Novel Therapeutics, London, UK

• Visiting Professor, McGill University Lady Davis Institute, Montreal, Canada

• University of Chicago, [Institute for Genomics and Systems Biology](http://www.igsb.org/labs/kevin-white/), Chicago, IL

• Physical Sciences Oncology Symposium, American Society of Cell Biology, Denver, CO

• Leukemia and Lymphoma Society Symposium at the American Society of Hematology, San Diego, CA

• AACR-EORTC Conference on Molecular Targets in Cancer, San Francisco, CA

• Conference on Biotherapeutics, Toronto, Canada

2012

• Washington University Siteman Cancer Center, St. Louis, MO

• University of Illinois, Chicago

• Epizyme, Inc. Cambridge, MA

• Plenary and Invited Speaker, AACR Annual Meeting, Chicago, IL

• Ninth International Workshop on Molecular Aspects of Myeloid Stem Cell Development and

 Leukemia Cincinnati, Ohio

• Loyola University Medical School, Maywood, IL

• Karolinksa Institute, Stockholm, Sweden

• Mount Sinai School of Medicine, New York, NY

• American Society of Hematology Annual Meeting, Atlanta, GA

• Visiting Professor, McGill University Lady Davis Institute, Montreal, Canada

• Myeloma Workshop, Phoenix, AZ

• Division of Hematology/Oncology, University of Chicago

2013

• Biannual Johns Hopkins Workshop on Epigenetic Changes in Cancer Therapeutics, Ashland, NC

• University of Maryland Cancer Center

• 3rd International Meeting on MPN, Florence, Italy

• XIVth International Myeloma Workshop, Kyoto, Japan

• MGH Cancer Center Conference on Enabling Technologies for Cancer Research, Beverly, MA

• FASEB Meeting on Hematological Malignancies, Saxtons River, VT

• Northern Illinois University, DeKalb, IL

• Visiting Professor, McGill University Lady Davis Institute, Montreal, Canada

• Epigenetics Congress, Boston, MA

• Ely Lilly and Company, Indianapolis, IN

• AbbVie, North Chicago, IL

• Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD

• Bristol Myers Squibb, Princeton, NJ

• Celgene, Summit, NJ

• 14th Meeting of the Chinese Association of Hematology

• 8th SINO-US Symposium on Medicine in the 21st Century

• Honorary Professorship Lecture, Jiao Tong University, Shanghai China

• Beijing Institute of Genomics, Beijing, China

2014

• Massachusetts General Hospital Cancer Center, Boston, MA

• Memorial Sloan Kettering Cancer Center, New York, NY

• 21st International Molecular Medicine Tri-Conference, San Francisco, CA

• Division of Hematology, Stanford University, Palo Alto, CA

• Division of Hematology/Oncology, The University of Michigan

• Department of Microbiology/Immunology, The University of Illinois, Chicago

• Meet the Professor, AACR Annual Meeting, San Diego, CA

• Invited Speaker, ASH Annual Meeting, Training Day, San Francisco, CA

• 2014 Cancer Molecular Research Therapeutics Association, Asilomar, CA

• AACR Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies

• The University of Nebraska Cancer Center. Omaha, Nebraska

• Discovery on Target: Histone Methyltransferases, Boston, MA

• L'Ospedale San Raffaele, Milan, Italy

• Distinguished Lecturer, McGill University, Lady Davis Institute, Montreal, Canada

• Bayer Pharmaceuticals, Berlin, Germany

• Novartis, Cambridge, MA

• Fred Hutchinson Cancer Research Center, Seattle, WA

• Evan P. Evans Foundation Symposium on Myelodysplastic Syndromes

• ASH/EHA Translational Research Training Institute

2015

• Clinical Translation of Epigenetics in Cancer Therapy, St. Augustine, FL

• Hematology Grand Rounds, MD Anderson Cancer Center, Houston, TX

• Department of Biochemistry and Molecular Genetics, Northwestern University

• ASH/EHA Translational Research Training Institute

• Myeloma 2015, Boston, MA

• AACR 2015 Annual Meeting Mentoring Sessions

• Department of Experimental Oncology, European Institute of Oncology, Milan, Italy

• Gordon Research Conference on Cancer Genetics and Epigenetics, Barga, Italy

• Gordon Research Conference on Genome Architecture in Cell Fate and Disease, Hong Kong, China

• FASEB Conference on Epigenetics, Chromatin and Transcription, Palm Beach, Florida

• H Foundation Symposium, Northwestern University

• Astra-Zeneca, Boston, MA

• Rutgers Medical School, Newark, NJ

2016

• Center for Cancer Research, National Cancer Institute

• Oregon Health Sciences University

• Midwest Chromatin Meeting, Grand Rapids, MI

• Children’s Hospital/Dana-Farber Cancer Institute, Boston, MA

• ASH/EHA Translational Research Training Institute, Milan, Italy

• University of Miami Epigenetics Conference, Miami, FL

• Department of Pharmacology, The University of Florida

• JCA-AACR Special Conference on Hematological Malignancies

• Dotan Symposium, Tel Aviv University, Tel Aviv, Israel

2017

• Gordon Research Conference on Cancer Genetics and Epigenetics, Barga, Italy- Vice Chair

• ASH/EHA Translational Research Training Institute, Milan, Italy

• Winship Cancer Center, Emory University, Atlanta, GA

• Sanford Burnham Prebys Discovery Institute, Orlando, FL

• Biannual Workshop on Epigenetic Changes in Cancer Therapeutics, Jekyll Island, GA

• AACR Annual Meeting Educational Session Chair and Speaker, Washington, DC

• AACR Conference on Hematologic Malignancies: Speaker and Conference Chair, Boston, MA

• FASEB Conference on Hematological Malignances, Saxton River, VT

• Celgene, San Diego, CA

• Brown University, Providence, RI

• Duke Cancer Institute, Durham, NC

• Cold Spring Harbor Asia, Suzhou, China

• American Clinical and Climatological Association, San Antonio, TX

2018

• University of California San Diego, San Diego, CA

• Ionis Pharmaceuticals, San Diego, CA

• Ichan School of Medicine at Mount Sinai, New York, NY

• University of Florida MD/PhD Program Retreat

• Abrahamson Cancer Center, The University of Pennsylvania, Philadelphia, PA

• Invited Speaker, AACR 2018 Annual Meeting, Chicago, IL

• Japan Society of Hematology, Kyoto, Japan

• Institute of Cancer Research, Columbia University

• University of Virginia, Charlottesville, VA

• Invited Speaker, ASH 2018 Annual Meeting, San Diego, CA

• University of Miami Epigenetics Symposium

• University of Miami Sylvester Comprehensive Cancer Center

2019

• Gordon Research Conference on Cancer Genetics and Epigenetics, Barga, Italy- Chair

• Thomas Jefferson University, Philadelphia, PA

• Biannual Workshop on Epigenetic Changes in Cancer Therapeutics, Arizona

• Department of Pathology, Yale University School of Medicine

• Keynote Speaker- Memorial Sloan Kettering Center for Hematological Malignancies Retreat

• Ohio State University, Columbus, OH

• 2019 Salk Cancer Mechanisms and Models, La Jolla CA

• Keynote speaker, Symposium in honor of the 70th Birthday of Daniel Tenen, Harvard Medical School

2020

• Loyola University Medical Center, Maywood, IL

• Department of Cell Biology and Anatomy, The University of Florida

• Hematological Malignancies Grand Rounds Memorial Sloan Kettering Cancer Center - Online

• DFCI/LLS Connect Science Lecture Series - Online

• City of Hope Cancer Center - Online

• NYU 3D Genome PO1 Symposium - Online

• Hematology/Oncology Grand Rounds, Weill Cornell Medical College - Online

• University of Miami Epigenetics Symposium- Online

2021

• The University of Wisconsin, McArdle Laboratory for Cancer Research Seminar Series-Online

• Vanderbilt University Cancer Center-Online

• City of Hope Cancer Center – Distinguished Lecture Series-Online

• UCSF Pediatric Malignancies Retreat- Online

• Live Like Bella Florida Department of Health Pediatric Cancer Symposium, Miami, Florida

2022

• Fox Chase Cancer Center, Philadelphia, PA

• University of Miami Epigenetics Symposium, Miami, FL

* AstraZeneca, Waltham MA
* Josep Carraras Institute, Barcelona, Spain
* Institute of Immunity & Transplantation, University College London, UK

2023

* Gordon Conference on Cancer Genetics and Epigenetics
* University of Kansas